Resonant (RESN) 10-K 28 Feb 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Feb. 26, 2018	Jun. 30, 2017
Document and Entity Information
Entity Registrant Name	Resonant Inc
Entity Central Index Key	1,579,910
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 46
Entity Common Stock, Shares Outstanding		19,911,602
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
CURRENT ASSETS
Cash and cash equivalents	$ 19,524	$ 5,084
Accounts receivable	50	56
Prepaid expenses and other current assets	536	160
Restricted cash	100	0
Investment held-to-maturity	0	4,747
TOTAL CURRENT ASSETS	20,210	10,047
PROPERTY AND EQUIPMENT
Fixed assets	3,212	2,269
Less: Accumulated depreciation and amortization	(1,858)	(1,275)
PROPERTY AND EQUIPMENT, NET	1,354	994
NONCURRENT ASSETS
Intangible assets, net	1,353	1,253
Restricted cash	0	100
Goodwill	824	789
Other assets	19	16
TOTAL NONCURRENT ASSETS	2,196	2,158
TOTAL ASSETS	23,760	13,199
CURRENT LIABILITIES
Accounts payable	708	905
Accrued expenses	314	35
Accrued salaries and payroll related expenses	1,936	1,765
Deferred revenue, current	143	279
Deferred rent, current	0	20
TOTAL CURRENT LIABILITIES	3,101	3,004
LONG-TERM LIABILITIES
Deferred revenue	0	46
Deferred rent	10	0
Deferred income taxes	1	16
TOTAL LIABILITIES	3,112	3,066
Commitments and contingencies (Note 9)
STOCKHOLDERS’ EQUITY
Common stock, $0.001 par value, 47,000,000 authorized and 12,468,647 issued and outstanding as of December 31, 2016, and 19,511,276 issued and outstanding as of December 31, 2017	20	12
Preferred stock, $0.001 par value, 3,000,000 authorized and none outstanding as of December 31, 2016 and 2017	0	0
Additional paid-in capital	88,447	56,331
Accumulated other comprehensive loss	(7)	(51)
Accumulated deficit	(67,812)	(46,159)
TOTAL STOCKHOLDERS’ EQUITY	20,648	10,133
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 23,760	$ 13,199

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	47,000,000	47,000,000
Common stock, shares outstanding	19,511,276	12,468,647
Common stock, shares, issued	19,511,276	12,468,647
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares outstanding	0	0

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
REVENUES	$ 653,000	$ 302,000
OPERATING EXPENSES
Research and development	10,045,000	6,895,000
General and administrative	9,644,000	8,697,000
TOTAL OPERATING EXPENSES	19,689,000	15,592,000
OPERATING LOSS	(19,036,000)	(15,290,000)
OTHER INCOME (EXPENSE)
Investment income	67,000	22,000
Warrant inducement expense	(2,688,000)	0
Other expense	(10,000)	(1,000)
TOTAL OTHER INCOME (EXPENSE)	(2,631,000)	21,000
LOSS BEFORE INCOME TAXES	(21,667,000)	(15,269,000)
Benefit from income taxes	14,000	22,000
NET LOSS	(21,653,000)	(15,247,000)
Foreign currency translation adjustment, net of tax	44,000	(51,000)
COMPREHENSIVE LOSS	$ (21,609,000)	$ (15,298,000)
NET LOSS PER SHARE - BASIC AND DILUTED (in dollars per share)	$ (1.44)	$ (1.57)
Weighted average shares outstanding — basic and diluted (shares)	15,015,446	9,691,115

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Balance (in shares) at Dec. 31, 2015		7,241,949
Balance at Dec. 31, 2015	$ 6,468,000	$ 7,000	$ 37,373,000	$ (30,912,000)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock for compensation (in shares)		262,201
Stock issued to consultants for services (in shares)		8,549
Stock issued to consultants for services	17,000		17,000
Stock-based compensation	2,323,000		2,323,000
Sales of common stock, net of offering costs (in shares)		4,711,880
Sales of common stock, net of offering costs	15,798,000	$ 5,000	15,793,000
Issuance of common stock in the acquisition of business assets (in shares)		125,000
Issuance of common stock in the acquisition of business assets	545,000		545,000
Exercise of warrants, cashless (in shares)		21,068
Exercise of warrants for cash (in shares)		98,000
Exercise of warrants for cash	280,000		280,000
Net loss	(15,247,000)			(15,247,000)
Foreign currency translation adjustment, net of tax	$ (51,000)				$ (51,000)
Balance (in shares) at Dec. 31, 2016	12,468,647	12,468,647
Balance at Dec. 31, 2016	$ 10,133,000	$ 12,000	56,331,000	(46,159,000)	(51,000)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock for compensation (in shares)		649,359
Issuance of common stock for compensation		$ 1,000	(1,000)
Stock-based compensation	4,136,000		4,136,000
Sales of common stock, net of offering costs (in shares)		3,603,817
Sales of common stock, net of offering costs	15,950,000	$ 4,000	15,946,000
Exercise of warrants, cashless (in shares)		147,847
Exercise of warrants for cash (in shares)		2,608,678
Exercise of warrants for cash	$ 11,960,000	$ 3,000	11,957,000
Exercise of stock options, cashless (in shares)		3,758
Exercise of warrants for cash (in shares)	32,928	29,170
Exercise of warrants for cash	$ 78,000		78,000
Net loss	(21,653,000)			(21,653,000)
Foreign currency translation adjustment, net of tax	$ 44,000				44,000
Balance (in shares) at Dec. 31, 2017	19,511,276	19,511,276
Balance at Dec. 31, 2017	$ 20,648,000	$ 20,000	$ 88,447,000	$ (67,812,000)	$ (7,000)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (21,653)	$ (15,247)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	721	694
Deferred tax benefit	(14)	(23)
Stock-based compensation	4,121	2,659
Non-cash warrant inducement expense	2,688	0
Non-cash investment income	0	(1)
Non-cash patent write-off	0	19
Non-cash loss on disposal of assets	2	1
Changes in assets and liabilities, net of effects of acquisition:
Accounts receivable	6	(19)
Prepaids and other current assets	(376)	(8)
Other assets	(3)	(1)
Accounts payable	(143)	56
Accrued expenses	163	(34)
Accrued salaries and payroll related expenses	208	980
Deferred revenue	(184)	299
Deferred rent	(10)	(34)
Net cash used in operating activities	(14,474)	(10,659)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of fixed assets	7	0
Purchases of property and equipment	(815)	(400)
Expenditures for patents and domain names	(332)	(177)
Payment for acquisition of business assets, net of acquired cash	0	(513)
Redemption of investments held-to-maturity	4,747	10,509
Purchase of investments held-to-maturity	0	(12,249)
Net cash provided by (used in) investing activities	3,607	(2,830)
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from the sale of common stock from private placement offerings	15,950	5,177
Net proceeds from the sale of common stock from underwritten public offering	0	10,621
Proceeds from exercise of warrants	9,272	280
Proceeds from exercise of stock options	78	0
Net cash provided by financing activities	25,300	16,078
Effects of currency translation on cash and cash equivalents	7	(6)
NET INCREASE IN CASH AND CASH EQUIVALENTS	14,440	2,583
CASH AND CASH EQUIVALENTS — Beginning of year	5,084	2,501
CASH AND CASH EQUIVALENTS — End of year	19,524	5,084
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Taxes	1	1
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES
Issuance of common stock in settlement of liability	119	110
Stock options issued in settlement of liability	332	0
Issuance of common stock in the acquisition of business assets	0	545
Property and equipment included in accounts payable	245	191
Property and equipment included in accrued liabilities	95	0
Patents included in accounts payable	$ 9	$ 117

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	ORGANIZATION AND DESCRIPTION OF BUSINESS Overview Resonant Inc. is a late-stage development company located in Goleta, California. We were incorporated in Delaware in January 2012 as a wholly owned subsidiary of Superconductor Technologies Inc., or STI, but had not conducted any operations through June 16, 2013. Resonant LLC, a limited liability company, was formed in California in May 2012. We commenced business on July 6, 2012 with initial contributions from our founders and STI. We changed our form of ownership from a limited liability company to a corporation in an exchange transaction in June 2013. We are the successor of Resonant LLC. We completed our initial public offering, or IPO, on May 29, 2014. We acquired all of the issued and outstanding capital stock of GVR Trade S.A, or GVR, on July 6, 2016. GVR is a wholly owned subsidiary of Resonant Inc. We have created an innovative software, intellectual property, or IP, and services platform that has the ability to increase designer efficiency, reduce the time to market and lower unit costs in the designs of filters for radio frequency, or RF, front-ends for the mobile device industry. The RF front-end, or RFFE, is the circuitry in a mobile device responsible for analog signal processing and is located between the device’s antenna and its digital circuitry. The software platform we are developing is based on fundamentally new technology that we call Infinite Synthesized Networks ® , or ISN ® , to configure and connect resonators, the building blocks of RF filters. Filters are a critical component of the RF front-end used to select desired radio frequency signals and reject unwanted signals. Our ISN ® platform allows us to develop unique, custom designs that address the increasing complexity of the RFFE due to carrier aggregation (the combining of multiple frequencies into a single data stream to increase throughput through higher data rates), or CA, by both reducing the size of the filter and improving performance. Our goal is to utilize our ISN ® platform to support our customers in reducing their time to develop complex filter and module designs, to access new classes of filter designs, and to do it more cost effectively. Additionally, our ISN ® platform has allowed us to expand our customer focus beyond just filter manufacturers by enabling a new class of customer - fabless filter manufacturers. These companies do not have their own internal filter fabrication facility, or Fab, and typically already would be supplying other products in the RFFE to the OEMs and as a result do not require a protracted, new vendor, qualification process in order to supply parts. It is through our existing customer relationships that we are able to facilitate these third-party Fab relationships, that leverage our ISN ® tools to deliver cutting edge filter designs to these fabless filter customers. We are commercializing our technology through the creation of filter designs that address the problems in the high growth RFFE industry created by the growing number of frequency bands in mobile devices. The worldwide adoption of Long Term Evolution, or LTE, as the global standard, and the use of mobile devices to access the Internet, has resulted in massive proliferation of frequency bands which, when combined with CA for higher data rates and multiple input multiple output, or MIMO, has resulted in an ever-increasing number and complexity of filters in the RFFE. We have developed and continue to expand a series of single-band designs for frequency bands presently dominated by larger and more expensive bulk acoustic wave, or BAW, filters. We are also developing multiplexer filter designs for two or more bands to address the CA requirements of our customers. We are using our ISN ® platform to efficiently integrate these designs into RF modules for our module customers. Finally, we are developing unique filter designs, enabled by ISN ® , to replace multiple filters and associated componentry for many bands, with higher performance. Currently, we are leveraging ISN ® to develop these designs targeted for either the Surface Acoustic Wave (SAW) or Temperature Compensated, Surface Acoustic Wave (TC-SAW) manufacturing processes. In order to succeed, we must convince RFFE suppliers that our filter designs can significantly reduce the size and cost of their products. We believe licensing our designs is the most direct and effective means of validating our ISN ® platform and related IP libraries to address this rapidly growing market. Our target customers make part or all of the RFFE. We intend to retain ownership of our designs, and we expect to be compensated through license fees and royalties based on sales of RFFE filters that incorporate our designs. We currently do not intend to manufacture or sell any physical products or operate as a contract design company developing designs for a fee. Capital Resources and Liquidity We are using the net proceeds from the sales of our common stock for product development to commercialize our technology, research and development, the development of our patent strategy and expansion of our patent portfolio, as well as for working capital and other general corporate purposes. Our costs include employee salaries and benefits, compensation paid to consultants, capital costs for research and other equipment, costs associated with development activities including travel and administration, legal expenses, sales and marketing costs, general and administrative expenses, and other costs associated with a late-stage development, publicly-traded technology company. However, this is highly dependent on the nature of our development efforts and our success in commercialization. We continue to add employees for research and development, as well as general and administrative functions, to support our efforts. Additionally, we continue to incur consulting expenses related to technology development and other efforts as well as legal and related expenses to protect our intellectual property. The amounts that we actually spend for any specific purpose may vary significantly and will depend on a number of factors including, but not limited to, our expected cash resources, the pace of progress of our commercialization and development efforts, actual needs with respect to product testing, research and development, market conditions, and changes in or revisions to our marketing strategies. In addition, we may invest in complementary products, technologies or businesses. We have earned minimal revenues since inception, and our operations have been funded with initial capital contributions and proceeds from the sale of equity securities and debt. At December 31, 2016 and December 31, 2017 , we had incurred accumulated losses totaling $46.2 million and $67.8 million , respectively. The losses are primarily the result of research and development costs associated with commercializing our technology, combined with start-up, financing and public company costs. We expect to continue to incur substantial costs for commercialization of our technology on a continuous basis because our business model involves developing and licensing custom filter designs. Our consolidated financial statements account for the continuation of our business as a going concern. We are subject to the risks and uncertainties associated with a new business. Our principal source of liquidity as of December 31, 2017 consists of existing cash and cash equivalents of $19.5 million . During the year ended December 31, 2017, we used $15.6 million of cash and investments for operating activities, the purchase of property and equipment, and expenditures for patents. Due to these conditions, along with planned growth, substantial doubt exists as to our ability to continue as a going concern. After evaluation of these conditions, we believe our current resources will provide sufficient funding for planned operations into the second half of 2018. If necessary, we will seek to raise additional capital from the sale of equity securities or the incurrence of indebtedness to allow us to continue operations. There can be no assurance that additional financing will be available to us on acceptable terms, or at all. Additionally, if we issue additional equity securities to raise funds, whether to existing investors or others, the ownership percentage of our existing stockholders would be reduced. New investors may demand rights, preferences or privileges senior to those of existing holders of common stock. Additionally, we may be limited as to the amount of funds we can raise pursuant to SEC rules and the continued listing requirements of NASDAQ. If we cannot raise needed funds, we might be forced to make substantial reductions in our operating expenses, which could adversely affect our ability to implement our business plan and ultimately our viability as a company. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty. We have a Form S-3 universal shelf registration statement on file with the SEC. The universal shelf registration statement on Form S-3 permits us to sell, in one or more public offerings, shares of our common stock, shares of preferred stock or debt securities, or any combination of such securities and warrants to purchase securities, for proceeds in an aggregate amount of up to $35.0 million, subject to limitations on the amount of securities we may sell in any twelve-month period. As of December 31, 2017, we have raised a total of $11.5 million of gross proceeds from the sale of 2,715,000 shares of our common stock, leaving approximately $23.5 million of securities available for issuance pursuant to the Form S-3. The Form S-3 will expire in May 2019.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Use of Estimates —The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. In the opinion of management, all adjustments (consisting of normal accruals) considered for a fair presentation have been included. Significant estimates made in preparing these financial statements include (a) assumptions to calculate the fair values of financial instruments, warrants and equity instruments and other liabilities and the deferred tax asset valuation allowance and (b) the useful lives for depreciable and amortizable assets. Actual results could differ from those estimates. In the opinion of management, all adjustments, including normal recurring accruals considered necessary for a fair presentation, have been included. Consolidation - The accompanying financial statements include the accounts of the Company and its wholly-owned subsidiary, GVR Trade, S.A. All significant intercompany balances and transactions have been eliminated. Cash and Cash Equivalents —We consider all liquid instruments purchased with a maturity of three months or less to be cash equivalents. Concentration of Credit Risk —We maintain checking accounts at one U.S. financial institution. The U.S. bank accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per account owner. GVR Trade S.A., our wholly owned Swiss-based subsidiary maintains checking accounts at one major national financial institution. Additionally, we maintain a checking account with a very minimal balance at one bank in South Korea, which is used to fund payroll and rent in South Korea. Management believes we are not exposed to significant credit risk due to the financial position of the depository institutions in which our deposits are held. Restricted Cash —Restricted cash at December 31, 2016 and December 31, 2017 represents cash held within a certificate of deposit with a financial institution, which serves as collateral for our corporate credit cards. The restriction on the cash will lapse in conjunction with the expiration of the use of the corporate credit cards. Investments —Securities held-to-maturity: Management determines the appropriate classification of debt securities at the time of purchase and reevaluates such designation as of each balance sheet date. Investment/debt securities are classified as held-to-maturity when we have the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest method. Such amortization is included in investment income. Interest on securities classified as held-to-maturity is included in investment income. When the fair value of an investment instrument classified as held-to-maturity is less than its amortized cost, management assesses whether or not: (i) we have the intent to sell the instrument or (ii) it is more likely than not that we will be required to sell the instrument before its anticipated recovery. If either of these conditions is met, we must recognize an other-than-temporary impairment for the difference between the instrument’s amortized cost basis and its fair value, and include such amounts in net securities gains (losses). For investment instruments that do not meet the above criteria and are not expected to be recovered at the amortized cost basis, the instrument is considered other-than-temporarily impaired. For these instruments, we separate the total impairment into the credit loss component and the amount of the loss related to other factors. In order to determine the amount of the credit loss, we calculate the recovery value by performing a discounted cash flow analysis based on the current cash flows and future cash flows management expects to recover. The discount rate is the effective interest rate implicit in the underlying instrument. The amount of the total other-than-temporary impairment related to credit loss is recognized in earnings and is included in net securities gains (losses). The amount of the total other-than-temporary impairment related to other factors is recognized in other comprehensive income. For investment instruments that have other-than-temporary impairment recognized through earnings, if through subsequent evaluation there is a significant increase in the cash flow expected, the difference between the amortized cost basis and the cash flows expected to be collected is accreted as interest income. During 2016, we invested in corporate paper and federally insured certificates of deposit that we have classified as held-to-maturity. As of December 31, 2016, the amortized cost value was $4.7 million with an unrealized loss of $2,000 and a fair value of $4.7 million . The investments consisted of $4.0 million of corporate paper, of which $3.0 million matured in January of 2017 and $1.0 million matured in February of 2017, and $747,000 of certificates of deposit which matured in increments of $249,000 between January and March of 2017. We did not recognize an other-than-temporary impairment gain or loss or a comprehensive gain or loss as of December 31, 2016. During 2017, we invested in commercial papers and certificates of deposit that were classified as investments held-to-maturity. Additionally, we maintained money market fund balances that were classified as cash and cash equivalents. As of December 31, 2017, all of our investments held-to-maturity have matured and we have no investments classified as held-to-maturity. We recorded investment income of $22,000 and $67,000 for the years ended December 31, 2016 and 2017, respectively, associated with our cash and investment accounts. Fair Value of Financial Instruments —We measure certain financial assets and liabilities at fair value based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The carrying amounts of our financial instruments, including cash equivalents, restricted cash, investments held-to-maturity, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. Accounts Receivable —Trade accounts receivable are stated net of allowances for doubtful accounts. Management estimates the allowance for doubtful accounts based on review and analysis of specific customer balances that may not be collectible, customer payment history and any other customer-specific information that may impact collectability of the receivable. Accounts are considered for write-off when they become past due and when it is determined that the probability of collection is remote. The was no allowance for doubtful accounts at December 31, 2016 and December 31, 2017. Property and Equipment —Property and equipment consists of leasehold improvements associated with our corporate offices, software purchased during the normal course of business, equipment and office furniture and fixtures, all of which are recorded at cost. During 2016, other property and equipment were acquired as part of the purchase of GVR and were initially recorded at their fair value. Depreciation and amortization is recorded using the straight-line method over the respective useful lives of the assets ranging from three to five years . Leasehold improvements are amortized over the shorter of lease term or useful life. Long-lived assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. Intangible Assets, net —Intangible assets are recorded at cost and amortized over the useful life. In the case of business combinations, intangible assets are recorded at fair value. At December 31, 2016 and December 31, 2017 , intangible assets, net, includes patents, domain name and other intangibles purchased from GVR, including customer relationships, technology and trademark. Intangible assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. Goodwill— At December 31, 2017 , goodwill represents the difference between the price paid to acquire GVR Trade and the fair value of the assets acquired, net of assumed liabilities. We review goodwill for impairment annually and whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. Revenue Recognition —Revenue consists primarily of fees received in connection with filter design projects with customers. Contracts may involve upfront non-refundable fees, intended to support our initial engineering product development efforts, as well as milestone payments based upon the successful completion of certain deliverables. In relation to the upfront non-refundable fees, we recognize revenue in accordance with the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 605, Revenue Recognition. We recognize revenue as the services are performed over the initial engineering filter design development period and when all of the following criteria have been met: persuasive evidence of an arrangement exists, services have been rendered, collection of the revenue is reasonably assured, and the fees are fixed or determinable. We record the expenses related to these projects in the periods incurred and they are generally included in research and development expense. In addition to the upfront non-refundable payments, the filter design projects include certain milestone payments upon successful filter design or a design stage completion. These filter design projects are associated with complex technology development, and as such we do not have certainty about our ability to achieve the program milestones. Achievement of the milestone is generally dependent on the filter design specifications and the milestone typically needs to be accepted by the customer. The payment associated with achieving the milestone is generally commensurate with our effort or the value of the deliverable and is generally non-refundable. We record revenue associated with the milestone payments in accordance with ASC Topic 605-28, Milestone Method, whereby we record revenue upon successful completion of the related milestone and when collection of the revenue is reasonably assured. We record the expenses related to these projects, generally included in research and development expense, in the periods incurred. During the years ended December 31, 2016 and 2017, we recorded revenue of $302,000 and $653,000 , respectively, primarily related to filter design projects. As of December 31, 2017 , we have recorded $143,000 in deferred revenue related primarily to our filter design development projects. Research and Development —Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with ASC Topic 730-10, Research and Development . Operating Leases —We lease office space and research facilities under operating leases. Certain lease agreements contain free or escalating rent payment provisions. We recognize rent expense under such leases on a straight-line basis over the term of the lease. Lease renewal periods are considered on a lease-by-lease basis in determining the lease term. Stock-Based Compensation —We account for employee stock options in accordance with ASC Topic 718, Compensation-Stock Compensation . For stock options issued to employees and directors we use the Black-Scholes option valuation model for estimating fair value at the date of grant. For stock options issued for services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC Topic 505-50 , Equity , or ASC 505-50, as amended. Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to performance, the value of these options, as calculated using the Black-Scholes option valuation model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options or warrants are fully vested. We account for restricted stock units issued to employees at fair value, based on the market price of our stock on the date of grant, net of estimated forfeitures. Compensation expense is recognized for the portion of the award that is ultimately expected to vest over the period during which the recipient renders the required services to the Company generally using the straight-line single option method. The fair value of non-employee restricted stock units awarded are remeasured as the awards vest, and the resulting increase or decrease in fair value, if any, is recognized as an increase or decrease to compensation expense in the period the related services are rendered. In the case of award modifications, we account for the modification by recognizing the effect of the modification in the period the award was modified. Stock-based compensation expense is included in research and development expenses and general and administrative expenses. Earnings Per Share, or EPS —EPS is computed in accordance with ASC Topic 260, Earnings per Share , and is calculated using the weighted average number of common shares outstanding during each period. Diluted EPS assumes the conversion, exercise or issuance of all potential common stock equivalents unless the effect is to reduce a loss or increase the income per share. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options (using the treasury stock method), the exercise of warrants (using the if-converted method) and the vesting of restricted stock unit awards. The following table presents the number of shares excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods below: Year Ended December 31, 2016 Year Ended December 31, 2017 Common stock warrants 2,915,559 3,730,255 Common stock options 801,690 1,082,490 Non-vested restricted stock unit awards 1,455,558 1,476,858 Total shares excluded from net loss per share attributable to common stockholders 5,172,807 6,289,603 Income Taxes —We account for income taxes in accordance with ASC Topic 740, Income Taxes , or ASC 740, which requires the recognition of deferred tax assets and liabilities for the future consequences of events that have been recognized in our condensed consolidated financial statements or tax returns. The measurement of the deferred items is based on enacted tax laws. In the event the future consequences of differences between financial reporting bases and the tax bases of our assets and liabilities result in a deferred tax asset, ASC 740 requires an evaluation of the probability of being able to realize the future benefits indicated by such asset. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion or the entire deferred tax asset will not be realized. As part of the process of preparing our consolidated financial statements, we are required to estimate our income tax expense in each of the jurisdictions in which we operate. We also assess temporary differences resulting from differing treatment of items for tax and accounting differences. We record a valuation allowance to reduce the deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. For the period when we were organized as a limited liability company, we were treated as a partnership for federal and state income tax purposes under the entity classification domestic default rules. As of December 31, 2016 and December 31, 2017 , no liability for unrecognized tax benefits was required to be reported. We recognize interest and penalties related to income tax matters in income taxes, and there were none for the years ended December 31, 2016 and December 31, 2017 , respectively. We have filed, or are in the process of filing, tax returns that are subject to audit by the respective tax authorities. Although the ultimate outcome would be unknown, we believe that any adjustments that may result from tax return audits are not likely to have a material, adverse effect on our consolidated results of operations, financial position or cash flows. Reclassifications —Certain amounts in the consolidated statement of operations for the year ended December 31, 2016 have been reclassified to conform to the current year presentation. Business Combinations— We record business combinations using the acquisition method of accounting and, accordingly, allocate the fair value of purchase consideration to the assets acquired and liabilities assumed based on their fair values at the acquisition date. The excess of the fair value of the purchase consideration over the fair value of the assets acquired and liabilities assumed is recorded as goodwill. The results of operations of the business acquired are included in our consolidated results of operations beginning on the date of acquisition. Foreign Currency Translation —The Swiss Franc has been determined to be the functional currency for the net assets of our Swiss-based subsidiary. We translate the assets and liabilities to U.S. dollars at each reporting period using exchange rates in effect at the balance sheet date and record the effects of the foreign currency translation in accumulated other comprehensive income (loss) in shareholders' equity. We translate the income and expenses to U.S. dollars at each reporting period using the average exchange rate in effect for the period and record the effects of the foreign currency translation as other comprehensive income (loss) in the consolidated statements of comprehensive loss. Gains and losses resulting from foreign currency transactions are included in net loss in the consolidated statements of comprehensive loss. Recent Accounting Pronouncements Revenue from Contracts with Customers— In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) . The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date , which defers the effective date of ASU No. 2014-09 for all entities by one year to annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. This ASU shall be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. Early adoption is permitted but not before the annual periods beginning after December 15, 2016, including interim periods within that reporting period. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net) . This ASU provides further guidance surrounding the recognition of revenue as well as guidance involving principal versus agent considerations. The effective date of this ASU is the same as ASU 2014-09. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing . This amendment provides clarification surrounding the identification of performance obligations and offers licensing implementation guidance. The effective date of this ASU is the same as ASU 2014-09. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606), Narrow-Scope Improvements and Practical Expedients, which provides further guidance surrounding certain aspects of ASU 2014-09. The effective date of this ASU is the same as ASU 2014-09. The new standards became effective for us on January 1, 2018 and we adopted at that time using the modified retrospective approach with a cumulative adjustment to reflect the initial impact recognized at the date of adoption. We believe the impact is not significant due to the relatively small number of contracts and nature of our contracts, which are primarily related to design development projects where the revenue is recognized over time under both the prior guidance and the new revenue recognition standard. We believe the adoption of the new standard will result in an increase to contract assets and a corresponding increase to retained earnings. The impact of the adoption is primarily related to the recognition of income from milestones within our contracts. Up until January 1, 2018, we recognized income related to milestones at the time when the milestone was achieved. Under the new guidance we are required to estimate the likelihood of such achievement, and recognize the income over the period of achievement. Leases— In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , a comprehensive new leases standard that amends various aspects of existing accounting guidance for leases. It will require recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The main difference between previous U.S. GAAP and the amended standard is the recognition of lease assets and lease liabilities by lessees on the balance sheet for those leases classified as operating leases under previous U.S. GAAP. The accounting applied by a lessor is largely unchanged from that applied under previous U.S. GAAP. As a result, we will have to recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing our right to use the underlying asset for the lease term on the balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. We are currently reviewing the two leases we have and are evaluating the effects of the new guidance on our consolidated financial statements. We do not expect it to have a material impact on our consolidated financial statements. Intangibles-Goodwill and Other— In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , which simplifies the accounting for goodwill impairments by eliminating step 2 from the goodwill impairment test. The amended guidance will become effective for us commencing in the first quarter of fiscal 2019. We are currently evaluating the impact of this new standard. Compensation-Stock Compensation— In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting , which provides clarity over the accounting for a change to the terms or conditions of a share-based payment award. The amendments in the update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. The amendments in this update should be applied prospectively to an award modification on or after the adoption date. This guidance became effective for us on January 1, 2018 and will be applied to all future share-based award modifications.

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND GOODWILL	INTANGIBLE ASSETS AND GOODWILL Intangible assets include patents, domain name and other intangibles purchased from GVR, including customer relationships, technology and a trademark. Certain patents were acquired from STI as a result of an asset contribution and were recorded at their carryover basis. The fair value of the patents remained substantially the same as their carrying value at the exchange date. In addition, we acquired other patents and the domain name www.resonant.com through the normal course of business. Intangibles acquired as part of the purchase of GVR were initially recorded at their fair value. Issued patents are amortized over their approximate useful life of 17 years, or 20 years in the case of new patents, once they are approved by their respective regulatory agency. For the patents acquired from STI, we are amortizing them over the remaining useful life of 1 to 12 years as of December 31, 2017 . The domain name is amortized over the approximate useful life of 10 years. The other intangibles acquired from GVR are amortized over their useful life of three to five years. Intangible assets consisted of the following at December 31, 2016 and 2017 : 2016 2017 Patents $ 1,132,000 $ 1,349,000 Domain Name 22,000 22,000 Client Base (1) 137,000 143,000 Trademark (1) 17,000 17,000 Backlog (1) 12,000 13,000 Technology 84,000 77,000 1,404,000 1,621,000 Less: accumulated amortization (151,000 ) (268,000 ) Net intangible assets $ 1,253,000 $ 1,353,000 (1) Includes the impact of foreign currency translation. The total impact at December 31, 2016 was $5,000 and the total impact at December 31, 2017 was $2,000 . During the year ended December 31, 2016 and 2017, we wrote-off $19,000 and $8,000 , respectively, of patents we are no longer pursuing. The write-offs are included in research and development expense. Amortization of intangible assets was $89,000 and $126,000 for the years ended December 31, 2016 and 2017 , respectively. The following table summarizes the estimated amortization expense relating to the intangible assets as of December 31, 2017 : Years ending December 31, 2018 $ 130,000 2019 103,000 2020 76,000 2021 66,000 2022 56,000 2023 and thereafter 418,000 Total amortization expense $ 849,000 Goodwill represents the excess of the purchase price over the fair value of the net assets acquired from GVR Trade (see Note 5). Goodwill is not amortized, but is subject to impairment tests on at least an annual basis and whenever circumstances suggest that goodwill may be impaired. Goodwill Balance at January 1, 2016 $ — Acquisition of GVR 824,000 Effect of currency translation (35,000 ) Balance at December 31, 2016 $ 789,000 Effect of currency translation $ 35,000 Balance at December 31, 2017 $ 824,000

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET	PROPERTY AND EQUIPMENT, NET Property and equipment, net consists of the following: 2016 2017 Cost: Computers, peripheral and scientific equipment $ 618,000 $ 1,016,000 Software 967,000 1,367,000 Leasehold Improvements 470,000 502,000 Office furniture and equipment 214,000 327,000 2,269,000 3,212,000 Less accumulated depreciation and amortization (1,275,000 ) (1,858,000 ) Property and equipment, net $ 994,000 $ 1,354,000 Depreciation expense for the years ended December 31, 2016 and December 31, 2017 was $604,000 and $594,000 , respectively. Disposals of property were $1,000 and $21,000 for the years ended December 31, 2016 and December 31, 2017 , respectively.

ACQUISITION OF GVR TRADE S.A.

ACQUISITION OF GVR TRADE S.A.	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
ACQUISITION OF GVR TRADE S.A.	ACQUISITION OF GVR TRADE S.A. On July 6, 2016 , we acquired all of the issued and outstanding capital stock of GVR Trade S.A. The purchase price, consisting of $661,000 in cash and 125,000 shares of our common stock with a fair value of $545,000 , based on a per share price of $4.36 as of the date of acquisition, was approximately $1.2 million . At the time of acquisition, we incurred approximately $92,000 of acquisition related expenses, which were included in general and administrative expenses for the year ended December 31, 2016. GVR is a wholly owned direct subsidiary of Resonant. As of the acquisition date, we recorded goodwill of approximately $824,000 , which represented the excess of the purchase price over the fair value of the assets acquired. The fair value for the assets acquired and liabilities assumed were based upon independent calculations and valuations. We review goodwill for impairment annually and whenever events or circumstances indicate that the carrying amount of the assets may not be recoverable. The purchase price was allocated based on the fair values of assets and liabilities as follows: Assets acquired Cash and cash equivalents $ 148,000 Other current assets 52,000 Property and equipment 23,000 Intangible assets Customer relationships 143,000 Developed technology 88,000 Trademarks and other 31,000 Total assets acquired 485,000 Liabilities assumed Current liabilities (35,000 ) Deferred tax liability (41,000 ) Deferred revenue, current (27,000 ) Total liabilities assumed (103,000 ) Net value of assets acquired and liabilities assumed 382,000 Total purchase price 1,206,000 Excess of purchase price over fair value of assets acquired and liabilities assumed - recorded as Goodwill $ 824,000 The acquisition was not material to our consolidated financial statements and we have included the financial results of the business acquisition in our consolidated financial statements from the date of acquisition. Our consolidated statements of comprehensive loss include $127,000 and $58,000 of net loss of GVR for the year ended December 31, 2016 and 2017 , respectively.

WARRANTS

WARRANTS	12 Months Ended
	Dec. 31, 2017
Warrants and Rights Note Disclosure [Abstract]
WARRANTS	WARRANTS From time to time, we have issued warrants to purchase shares of common stock. These warrants have been issued in connection with financing transactions and for consulting services. Our warrants are subject to standard anti-dilution provisions applicable to shares of our common stock. Bridge Warrants In connection with and as an inducement to make the bridge loans in January and March 2013 , Resonant LLC issued to each of our three founders 5 -year warrants to purchase Class B units of Resonant LLC at an exercise price of $0.40 per unit, which we refer to as the Bridge Warrants. The Bridge Warrants were issued in two tranches, at the same time the bridge loan was funded, with each founder receiving warrants for 20,833 Class B units on each of January 31, 2013 (for a total of 62,499 Class B units) and March 19, 2013 (for a total of 62,499 Class B units). The founders paid an aggregate of $1,000 in cash for the Bridge Warrants. On June 17, 2013 , in connection with our acquisition of all of the outstanding membership interests of Resonant LLC in an exchange transaction, the founders exchanged their Bridge Warrants to purchase an aggregate of 124,998 Class B units of Resonant LLC for Bridge Warrants to purchase an aggregate of 249,999 shares of our common stock at an exercise price of $0.20 per share. All other terms of the Bridge Warrants remained the same. Consulting Warrant, Financing Warrant and Underwriting Warrant Upon consummation of our Senior Convertible Note financing, for business consulting services provided by MDB Capital Group, LLC, or MDB, we issued to MDB a 7 -year warrant to purchase 222,222 shares of our common stock at an exercise price of $0.01 per share, which we refer to as the Consulting Warrant. The Consulting Warrant is exercisable six months after the completion of our initial public offering, or IPO, in 2014 and prior to June 15, 2020 . In addition, for placement agent services provided by MDB in connection with our Senior Convertible Note financing, we issued to MDB a 7 -year warrant to purchase shares of our common stock, which we refer to as the Financing Warrant. The Financing Warrant is exercisable six months after the completion of our IPO and prior to June 15, 2020 . The Financing Warrant is exercisable for a number of shares of our common stock equal to $700,000 divided by the Financing Warrant’s exercise price. In connection with the closing of our IPO, we also issued a third warrant to MDB related to their role as the sole underwriter for our IPO, which we refer to as the Underwriting Warrant. We issued them a 5 -year warrant to purchase 310,500 shares of common stock at an exercise price of $7.50 per share. The warrant was not exercisable until November 24, 2014 ( 180 -days from the date of the underwriting agreement) and expires May 28, 2019 . Investor Relations Warrants In August 2014 and October 2014 , we entered into agreements with our investor relations firm, or IR Firm, and an IR consultant to provide us with investor relations services. Pursuant to the IR Firm agreement, in addition to monthly cash compensation, we issued to the IR Firm a 3 -year consulting warrant, or IR Consulting Warrant, for the purchase of 42,000 shares of common stock that became fully vested on July 21, 2015 . The IR Consulting Warrant had an exercise price of $8.31 and expired, unexercised, on July 17, 2017 . Pursuant to our agreement with the IR consultant, in addition to monthly cash compensation, we issued to the IR consultant a 4 -year consulting warrant, or IR Warrant, for the purchase of 6,000 shares of common stock that became fully vested on September of 2015. The IR Warrant has an exercise price of $6.50 and expires on September 30, 2018 . There was no expense recorded for the years ended December 31, 2016 or 2017 related to the investor relations warrants as they had been fully expensed as of December 31, 2015 . Private Placement Warrants - 2016 In April 2016 , we issued warrants to purchase 1,996,880 shares of our common stock at an exercise price of $2.86 in connection with our private placement sale of 1,996,880 shares of common stock. The warrants are exercisable for a period commencing 6 months and ending 36 months after the closing of the financing on April 25, 2016 . We also issued to the placement agents in the financing, warrants to purchase an aggregate of 99,844 shares of our common stock at an exercise price of $2.86 for a period commencing 6 months and ending 36 months after the closing. We refer to these warrants as Private Placement Warrants - 2016 . We estimated the fair value of the Private Placement Warrants - 2016 at $2,500,000 using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $2.90 per share, time to maturity of 3 years , volatility of 60% , zero expected dividend rate and risk free rate of 0.97% . The allocation of the fair value of these warrants was included in additional paid-in capital on the consolidated balance sheet. In December 2017 , we entered into Warrant Exercise Agreements with certain holders of Private Placement Warrants - 2016 to induce the exercise of 836,780 warrants in full. Pursuant to the agreements, the warrant holders exercised in full the warrants and purchased an aggregate of 836,780 shares of our common stock at an exercise price of $2.86 per share, for an aggregate exercise price of approximately $2.4 million and we paid the warrant holders aggregated inducement fees of approximately $239,000 , which resulted in net proceeds to us of $2.2 million . The inducement offer included in the Warrant Exercise Agreements was considered a modification to the warrants upon acceptance by the warrant holders. Upon modification of the warrants we were required to remeasure the warrants. We estimated the fair value of the Private Placement Warrants - 2016 immediately prior to modification at $3.8 million using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $6.96 to $7.42 per share, time to maturity of 1.42 years, volatility of 60% , zero expected dividend rate and risk free rates of 1.70% to 1.74% . We estimated the fair value of the Private Placement Warrants - 2016 upon modification at $3.9 million using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $6.96 to $7.42 per share, time to maturity of 1 day , volatility of 10% , zero expected dividend rate and risk free rates of 1.14% to 1.21% . The change in fair value was $166,000 , and when combined with the cash inducement of $239,000 , resulted in $73,000 of expense, which was recorded as warrant inducement expense. Underwriting Warrants - Public Offering 2016 In September 2016 , we issued warrants to purchase 135,750 shares of our common stock at an exercise price of $4.25 to the underwriter of our public offering of 2,715,000 shares of common stock. The warrants are exercisable for a 2 year period commencing September 9, 2017 . We refer to these warrants as Underwriting Warrants - Public Offering 2016. We estimated the fair value of the Underwriting Warrants -Public Offering 2016 at $475,000 using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $6.54 per share, time to maturity of 3 years , volatility of 60% , zero expected dividend rate and risk free rate of 0.90% . The allocation of the fair value of these warrants was included in additional paid-in capital on the consolidated balance sheet. Private Placement Warrants - February 2017 In February 2017 , we issued warrants to purchase 1,626,898 shares of our common stock at an exercise price of $8.25 in connection with our private placement sale of 1,626,898 shares of common stock. The warrants were exercisable for a period commencing 6 months and ending 30 months after the closing of the financing. We refer to these warrants as Private Placement Warrants - February 2017 . We estimated the fair value of the Private Placement Warrants - February 2017 at $2,084,000 using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $4.91 per share, time to maturity of 3 years , volatility of 60% , zero expected dividend rate and risk free rate of 1.50% . The allocation of the fair value of these warrants was included in additional paid-in capital on the consolidated balance sheet. On December 19, 2017, we entered into a Warrant Exercise Agreement with the holder of Private Placement Warrants - February 2017 to induce the exercise of the 1,626,898 warrants in full. Pursuant to the agreement, the warrant holder exercised in full the warrant and purchased 1,626,898 shares of our common stock at an exercise price of $8.25 per share, for an aggregate exercise price of approximately $13.4 million and we paid the warrant holder an inducement fee of approximately $6.7 million , which resulted in net proceeds to us of $6.7 million . The inducement offer included in the Warrant Exercise Agreement was considered a modification to the warrant upon acceptance by the warrant holder. Upon modification of the warrant we were required to remeasure the warrant. We estimated the fair value of the Private Placement Warrants - February 2017 immediately prior to modification at $4.1 million using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $8.18 per share, time to maturity of 1.67 years , volatility of 60% , zero expected dividend rate and risk free rate of 1.78% . We estimated the fair value of the Private Placement Warrants - February 2017 upon modification at $6.7 million using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $8.18 per share, time to maturity of 1 day , volatility of 10% , zero expected dividend rate and risk free rate of 1.25% . The change in fair value was $4.1 million , and when combined with the cash inducement of $6.7 million , resulted in $2.6 million of expense, which was recorded as warrant inducement expense. Private Placement Warrants - September 2017 In September and October 2017, we issued warrants to purchase an aggregate of 1,976,919 shares of our common stock at an exercise price of $4.85 in connection with our private placement sale of 1,976,919 shares of common stock. The sale was completed in two tranches with the first tranche, which closed on September 28, 2017 , including 1,745,581 warrants, and the second tranche, which closed on October 2, 2017 , including 231,338 warrants. The warrants are exercisable for a period commencing 6 months and ending 36 months after the closing of the financing. Collectively, we refer to these warrants as Private Placement Warrants - September 2017. We estimated the total fair value of the Private Placement Warrants - September 2017 at $3.6 million using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $4.49 for the first tranche and $4.69 per share for the second tranche, time to maturity of 3 years , volatility of 60% , zero expected dividend rate and risk free rates of 1.59% for the first tranche and 1.63% for the second tranche. The allocation of the fair value of these warrants was included in additional paid-in capital on the consolidated balance sheet. Placement Agent Warrants - 2017 In addition to the Private Placement Warrants - September 2017 issued in connection with our private placement sale of 1,976,919 shares of our common stock, we also issued to the placement agent, warrants to purchase a total of 98,846 shares of our common stock at an exercise price of $4.85 per share. Upon closing of the first tranche on September 28, 2017, we issued 87,279 warrants, and upon closing the second tranche, we issued 11,567 warrants. The warrants are exercisable for a period commencing 6 months and ending 36 months after the closing of the financing. Collectively, we refer to these warrants as Placement Agent Warrants - 2017. We estimated the fair value of the Placement Agent Warrants - 2017 at $174,000 using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $4.49 per share for the first tranche and $4.69 per share for the second tranche, time to maturity of 3 years , volatility of 60% , zero expected dividend rate and risk free rates of 1.59% for the first tranche and 1.63% for the second tranche. The allocation of the fair value of these warrants was included in additional paid-in capital on the consolidated balance sheet. A roll-forward of warrant activity from January 1, 2016 to December 31, 2016 is shown in the following table: Issued and Warrants Warrants Issued and Bridge Warrants 249,999 — — 249,999 Consulting Warrant 117,778 — (19,778 ) (1) 98,000 Financing Warrants 78,186 — — 78,186 Underwriting Warrant 310,500 — — 310,500 IR Consulting Warrants 48,000 — — 48,000 Private Placement Warrants - 2016 — 2,096,724 (101,600 ) (2) 1,995,124 Underwriting Warrants - Public Offering 2016 — 135,750 — 135,750 804,463 2,232,474 (121,378 ) 2,915,559 (1) During the year ended December 31, 2016, there were 19,778 common stock warrants that were exercised through a cashless exercise which netted 19,693 shares being issued. (2) During the year ended December 31, 2016, there were 3,600 common stock warrants that were exercised through a cashless exercise which netted 1,375 shares being issued. Additionally, there were 98,000 warrants exercised for cash. A roll-forward of warrant activity from January 1, 2017 to December 31, 2017 is shown in the following table: Issued and Warrants Warrants Issued and Bridge Warrants 249,999 — — 249,999 Consulting Warrant 98,000 — (85,777 ) (1 ) 12,223 Financing Warrants 78,186 — (15,656 ) (2 ) 62,530 Underwriting Warrant 310,500 — — 310,500 IR Consulting Warrants 48,000 — (42,000 ) (3 ) 6,000 Private Placement Warrants - 2016 1,995,124 — (1,104,061 ) (4 ) 891,063 Underwriting Warrants - Public Offering 2016 135,750 — (13,575 ) (5 ) 122,175 Private Placement Warrants - February 2017 — 1,626,898 (1,626,898 ) (6 ) — Private Placement Warrants - September 2017 — 1,976,919 — 1,976,919 Placement Agent Warrants - 2017 — 98,846 — 98,846 2,915,559 3,702,663 (2,887,967 ) 3,730,255 (1) During the year ended December 31, 2017, there were 85,777 common stock warrants that were exercised through cashless exercises which netted 85,620 shares being issued. (2) During the year ended December 31, 2017, there were 15,656 common stock warrants that were exercised through a cashless exercise which netted 6,842 shares being issued. (3) During the year ended December 31, 2017, 42,000 warrants expired. (4) During the year ended December 31, 2017, there were 122,281 common stock warrants that were exercised through cashless exercises which netted 49,063 shares being issued. Additionally, there were 981,780 warrants that were exercised for cash, which included 836,780 warrants exercised subject to inducement, which offered the warrant holder an inducement fee of $0.29 /share to exercise the warrant in full for cash immediately. (5) During the year ended December 31, 2017, there were 13,575 common stock warrants that were exercised through a cashless exercise which netted 6,322 shares being issued. (6) During the year ended December 31, 2017, there were 1,626,898 common stock warrants that were exercised for cash. The warrants were exercised subject to inducement, which offered the warrant holder an inducement fee of $4.13 /share to exercise the warrant in full for cash immediately.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY Common Stock Pursuant to our amended and restated certificate of incorporation, we are authorized to issue 47,000,000 shares of common stock. Holders of our common stock are entitled to dividends as and when declared by the board of directors, subject to rights and holders of all classes of stock outstanding having priority rights to dividends. There have been no dividends declared to date. Each share of common stock is entitled to one vote. On April 25, 2016 , we completed the private placement sale of 1,996,880 units at a price of $2.985 per unit to institutional and individual investors, which included existing investors, executives and board members. Each unit consists of one share of our common stock and one warrant to purchase one share of our common stock at an exercise price of $2.86 for a period commencing 6 months and ending 36 months after the closing of the financing. We also issued to the placement agents in the financing, warrants to purchase an aggregate of 99,844 shares of our common stock at an exercise price of $2.86 for a period commencing 6 months and ending 36 months after the closing. Gross proceeds were $6.0 million with net proceeds of $5.2 million after deducting placement agent fees and offering expenses. We registered for resale by the investors the shares of common stock, and the shares of common stock issuable upon exercise of the warrants, purchased by the investors in the financing pursuant to a registration statement that was declared effective by the SEC in May 2016 . On September 14, 2016 , we completed the sale of 2,715,000 shares of common stock at a price of $4.25 per share in an underwritten public offering. We also issued to the underwriter warrants to purchase 135,750 shares of our common stock at an exercise price of $4.25 exercisable for a 2 year period commencing September 9, 2017 . Gross proceeds were $11.5 million with net proceeds of $10.6 million after deducting underwriter fees and offering expenses. The shares were issued pursuant to a shelf registration statement that we filed with the SEC, which became effective in May 2016 . On February 22, 2017 , we completed the private placement sale of 1,626,898 units at a price of $4.61 per unit to one investor. Each unit consists of one share of our common stock and one warrant to purchase one share of our common stock at an exercise price of $8.25 for a period commencing 6 months and ending 30 months after the closing of the financing. Gross proceeds were $7.5 million . We incurred $29,000 of legal expenses in connection with the financing. We registered for resale by the investor the shares of common stock, and the shares of common stock issuable upon exercise of the warrants, purchased by the investor in the financing pursuant to a registration statement that was declared effective by the SEC in April 2017 . On October 2, 2017 , we completed the private placement sale of 1,976,919 units. Each unit consisted of one share of our common stock and one warrant to purchase one share of our common stock at an exercise price of $4.85 per share for a period commencing 6 months and ending 36 months from September 28, 2017 , the date of the first closing of the offering. The sale closed in two rounds with the first closing on September 28, 2017 which included the private placement sale of 1,745,581 units at a price of $4.70 per unit to institutional and individual investors. Gross proceeds in the first closing were $8.2 million with net proceeds of $7.5 million after deducting placement agent fees and offering expenses. The second closing, completed on October 2, 2017 , was for 231,338 units and gross proceeds of $1.1 million with net proceeds of $1.0 million after deducting placement agent fees and offering expenses. We also issued to the placement agent, warrants to purchase an aggregate of 98,846 shares of our common stock at an exercise price of $4.85 per share for a period commencing 6 months and ending 36 months from September 28, 2017 . We have a Form S-3 universal shelf registration statement on file with the SEC. The universal shelf registration statement on Form S-3 permits us to sell, in one or more public offerings, shares of our common stock, shares of preferred stock or debt securities, or any combination of such securities and warrants to purchase securities, for proceeds in an aggregate amount of up to $35.0 million . As of December 31, 2017, we have raised a total of $11.5 million of gross proceeds from the sale of 2,715,000 shares of our common stock, leaving approximately $23.5 million of securities available for issuance pursuant to the Form S-3. The Form S-3 will expire in May 2019 . Preferred Stock Pursuant to our amended and restated certificate of incorporation, we are authorized to issue 3,000,000 shares of preferred stock. The board of directors has the authority, without action by our stockholders, to designate and issue shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. To-date, no preferred shares have been issued.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION 2014 Omnibus Incentive Plan In January 2014, our board of directors approved the 2014 Omnibus Incentive Plan and amended and restated the plan in March 2014. Our stockholders approved the Amended and Restated 2014 Omnibus Incentive Plan, or the 2014 Plan, in March 2014. Our 2014 Plan initially permitted the issuance of equity based instruments covering up to a total of 1,400,000 shares of common stock. In June 2016, our board of directors and stockholders approved an increase of 1,300,000 shares and in June 2017 approved an additional increase of 3,250,000 shares of common stock bringing the total shares allowed under the plan to 5,950,000 . Option Valuation We have computed the fair value of options granted to employees and non-employees using the Black-Scholes option valuation model. The compensation costs of non-employee arrangements are subject to re-measurement at each reporting period over the vesting terms as earned. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The expected term used for options issued to non-employees is the contractual life and the expected term used for options issued to employees is the estimated period of time that options granted are expected to be outstanding. We have estimated the expected life of our employee stock options using the “simplified” method, whereby, the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to our lack of sufficient historical data. For consultants we use an estimated expected life of the remaining term of the stock option grant, which is initially ten years . Since our stock has not been publicly traded for a sufficiently long period of time, we are utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within our industry. The risk-free interest rate was determined from the U.S. Treasury's Daily Treasury Yield Curve Rate with a term that best approximates the expected term of the instrument being valued. Stock Options to Employees and Non-Employees During the years ended December 31, 2016 and 2017 , we granted incentive stock options for the purchase of 346,500 and 488,300 shares, respectively, of our common stock to our employees and consultants. The options granted in 2016 have an exercise price range of $1.93 per share to $5.50 per share with a term of ten years. The options granted in 2017 have an exercise price range of $4.36 per share to $7.80 per share with a term of ten years. The options vest over various periods, generally quarterly over sixteen quarters. The options granted in 2016 had an aggregate grant date fair value of $627,000 and the options granted in 2017 had an aggregate grant date fair value of $1.4 million utilizing the Black-Scholes option valuation model. We estimated the fair value of stock options awarded during the years ended December 31, 2016 and 2017 using the Black-Scholes option valuation model. The fair values of stock options granted for the years were estimated using the following assumptions: Option Grants Awarded During the Year Ended December 31, 2016 Option Grants Awarded During the Year Ended December 31, 2017 Stock Price $1.93 - $5.50 $4.36 - $7.80 Dividend Yield 0% 0% Expected Volatility 60.0% 60.0% Risk-free interest rate 1.30% - 2.06% 1.95% - 2.37% Expected Term 7 years 7 to 10years Stock-based compensation expense related to stock options for employees was $529,000 and $435,000 for the years ended December 31, 2016 and 2017, respectively. We estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from our estimates. We use historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent that actual forfeitures differ from our estimates, the difference is recorded as a cumulative adjustment in the period the estimates were revised. For the period from January 1, 2016 to June 30, 2016 we applied a forfeiture rate of zero as there had been minimal forfeitures to date. Beginning July 1, 2016, we applied a forfeiture rate of six percent, which is reflected in our stock-based compensation expense related to stock options for the year ended December 31, 2016 and 2017. In August 2016, we modified certain stock options previously granted to a former executive. The modification was made in connection with the executive’s termination. The modification included accelerated vesting of stock options to purchase 26,876 shares of common stock as well as an extension of the exercise period for all vested shares, including stock options to purchase 43,438 shares of common stock. As a result of the modification, additional stock compensation expense of $48,000 was recognized for the year December 31, 2016. In January 2017, we modified certain stock options previously granted to a former executive. The modification was made in connection with the executive’s termination. The modification included accelerated vesting of stock options to purchase 8,752 shares of common stock as well as an extension of the exercise period for all vested shares, including stock options to purchase 17,504 shares of common stock. As a result of the modification, additional stock compensation expense of $19,000 was recognized for the year ended December 31, 2017. For stock options paid in consideration of services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC 505-50. Non-employee stock option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to performance, the value of these stock options, as calculated using the Black-Scholes option valuation model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of stock options granted to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options are fully vested. Stock-based compensation expense related to stock options for consultants was $27,000 and $9,000 for the years ended December 31, 2016 and 2017 , respectively. Stock Option Award Activity The following is a summary of our stock option activity during the year ended December 31, 2016 : Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Outstanding, January 1, 2016 565,050 $ 6.57 $ 4.25 7.84 Granted 346,500 3.03 1.81 8.51 Exercised — — — — Canceled/Forfeited (109,860 ) 5.08 3.32 — Outstanding, December 31, 2016 801,690 $ 5.25 $ 3.32 7.40 Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Exercisable, January 1, 2016 302,415 $ 6.25 $ 4.11 7.07 Vested 173,010 5.37 3.43 5.95 Exercised — — — — Canceled/Forfeited (56,251 ) 5.87 3.87 — Exercisable, December 31, 2016 419,174 $ 5.94 $ 3.86 6.00 The following is a summary of our stock option activity during the year ended December 31, 2017 : Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Outstanding, January 1, 2017 801,690 $ 5.25 $ 3.32 7.40 Granted 488,300 4.62 2.79 9.51 Exercised (32,928 ) 2.37 1.41 — Canceled/Forfeited (174,572 ) 6.4 4.18 — Outstanding, December 31, 2017 1,082,490 $ 4.87 $ 3.00 8.38 Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Exercisable, January 1, 2017 419,174 5.94 3.86 6.00 Vested 457,338 4.57 2.77 8.65 Exercised (32,928 ) 2.37 1.41 — Canceled/Forfeited (139,281 ) 6.65 4.38 — Exercisable, December 31, 2017 704,303 5.08 3.17 8.15 The following table presents information related to stock options outstanding and exercisable at December 31, 2017 : Options Outstanding Options Exercisable Exercise Price Outstanding Number of Options Weighted Average Remaining Life In Years Exercisable Number of Options $1.93 - $2.00 149,000 8.10 65,198 $3.83 - $4.70 523,190 9.38 343,198 $5.06 - $6.00 250,000 6.67 197,199 $6.18 – $7.20 70,000 6.67 40,945 $7.54 – $7.80 67,800 6.96 41,817 $8.06 - $12.98 22,500 7.04 15,946 1,082,490 8.15 704,303 As of December 31, 2017 , there was $925,000 of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted average vesting period of approximately 2.8 years. The aggregate intrinsic value of outstanding options and options vested as of December 31, 2016 were $647,000 and $146,000 , respectively, representing options whose exercise price was less than the closing fair market value of our common stock of $5.05 per share. The aggregate intrinsic value of outstanding options and options vested as of December 31, 2017 were $2.9 million and $1.7 million , respectively, representing options whose exercise price was less than the closing fair market value of our common stock of $7.47 per share. There were no excess tax benefits realized for tax deductions from stock options exercised during the year ended December 31, 2016 as no options were exercised. There were no excess tax benefits realized for tax deductions from stock options exercised during the year ended December 31, 2017 as we have recorded a full valuation allowance against our deferred income taxes. Restricted Stock Units Activity We account for restricted stock units issued to employees at fair value, based on the market price of our stock on the date of grant, net of estimated forfeitures. The fair value of non-employee restricted stock units awarded are re-measured as the awards vest, and the resulting increase in fair value, if any, is recognized as expense in the period the related services are rendered. During the years ended December 31, 2016 and 2017 we recorded $1.7 million and $2.6 million , respectively, of stock-based compensation related to the restricted stock unit shares that have been issued to-date. A summary of restricted stock unit activity for the year ended December 31, 2016 is as follows: Number of Restricted Share Units Weighted-Average Grant-Date Fair Value Per Share Outstanding at January 1, 2016 375,629 $ 6.16 Granted 1,383,159 3.22 Vested (262,201 ) 4.54 Forfeited (41,029 ) 5.64 Outstanding at December 31, 2016 1,455,558 $ 3.64 A summary of restricted stock unit activity for the year ended December 31, 2017 is as follows: Number of Restricted Share Units Weighted-Average Grant-Date Fair Value Per Share Outstanding at January 1, 2017 1,455,558 $ 3.64 Granted 722,400 5.37 Vested (649,359 ) 4.26 Forfeited (51,741 ) 5.40 Outstanding at December 31, 2017 1,476,858 $ 4.96 As of December 31, 2017 , there was $5.0 million of unrecognized compensation expense related to unvested restricted stock unit agreements which is expected to be recognized over a weighted-average period of approximately 2.4 years . For restricted stock unit awards subject to graded vesting, we recognize compensation cost on a straight-line basis over the service period for the entire award. Market-based Awards In August 2016, we granted 250,000 market-based restricted stock units to an executive. The restricted stock units are subject to market-based vesting requirements, measured quarterly, based on the average of (a) the average high daily trading price of our common stock for each trading day during the last month of the applicable calendar quarter and (b) the average low daily trading price of our common stock for each trading day during the last month of the applicable calendar quarter, each as reported by The Nasdaq Stock Market, LLC. The restricted stock units are eligible to be earned on a quarterly basis based on a linear interpolation of the applicable share price, or in the case of a liquidation event, on the day of (or in connection with) such liquidation event based on the applicable transaction price. Once earned, the restricted stock units vest 50% on the date such restricted stock units become earned and 50% on September 30, 2019 . We recognize compensation expense for restricted stock units with market-based conditions using a graded vesting model, based on the probability of the performance condition being met, net of estimated pre-vesting forfeitures. The share price on the date of issuance was $5.06 per share. To determine the fair value of the award we used a Monte Carlo simulation which simulates future stock prices for the Company and, hence, shares vested, pursuant to the award. A key input into the model is the expected volatility for our stock. This estimate considered the historical volatility of our stock as well as the stock price volatility of guideline public companies. The fair value was determined to be $74,000 . For the years ended December 31, 2016 and 2017, we recognized $8,000 and $24,000 , respectively, of stock compensation expense in connection with this award, which is included in general and administrative expenses. The unamortized expense related to this award is $41,000 and is expected to be recognized over 1.8 years. Incentive Bonus Awards We provide eligible employees, including executives, the opportunity to earn bonus awards upon achievement of predetermined performance goals and objectives. The purpose is to reward attainment of company goals and/or individual performance objectives, with award opportunities expressed as a percentage of base salary. Bonuses can be measured and paid quarterly and/or annually, and are paid in cash, equity or a combination of cash and equity, in the discretion of our compensation committee. 2015 Incentive Bonus Program During 2015, our employees and executives participated in the 2015 Incentive Bonus Program. The awards under this program contained a combination of service conditions and performance conditions based on the achievement of specified performance thresholds approved by the board. The performance bonus amounts were based on each individual’s salary paid during the year multiplied by a defined bonus multiplier percentage, plus an additional 10% bonus for non-executive employees. In February 2016 , upon board approval, we granted 90,265 restricted stock unit awards, of which 45,140 shares vested on the issuance date and the remaining shares vested on January 1, 2017 . For the year ended December 31, 2015, we recognized stock compensation expense of $121,000 in connection with the program, which was included in accrued salaries and payroll related expenses as of year-end. The accrual was released upon issuance of the equity awards in 2016. For the year ended December 31, 2016 we recognized additional stock compensation expense of $44,000 , which is included in the restricted stock unit expense discussed under "Restricted Stock Units Activity" above. There was no expense recorded during the year ended December 31, 2017 in connection with this program. 2016 Incentive Bonus Program During 2016, our employees and executives participated in the 2016 Incentive Bonus Program. The program provided for the award of annual bonuses if certain performance goals, based on revenue and certain other non-monetary targets, were attained in our 2016 fiscal year. The bonus was payable in cash, restricted stock units or a combination of cash and restricted stock units, as determined by our compensation committee, with the number of restricted stock units to be determined by dividing the dollar value to be paid in restricted stock units by the average closing price of our common stock for the ten trading days ending on the last trading day of 2016. The restricted stock units would have vested in full on the tenth business day following grant. Although the specific performance objectives were not achieved, it was determined that a discretionary bonus would be awarded under the program based on the significant achievements made toward the objectives during the year. The payment method and terms remained the same as the original bonus program. The discretionary awards were granted in February of 2017 , and consisted of cash awards totaling $688,000 and equity awards in the form of restricted stock units and stock options to vest in full 10 days following grant. The equity awards consisted of 27,390 restricted stock units with a grant date fair value of $119,000 based on the grant date share price of $4.36 and 125,880 stock options with a grant date fair value of $332,000 using the Black-Scholes option valuation model using the following assumptions: stock price of $4.36 ; dividend yield of 0% ; expected volatility of 60% ; risk-free rate of 2.15% and expected life of 7 years . For the year ended December 31, 2016, we recorded stock compensation expense of $451,000 in connection with these equity awards and salary expenses of $688,000 related to the cash portion of awards under this program. The total expense for these awards, $1.1 million , was recorded in the fourth quarter of 2016 and was included in accrued salaries and payroll-related expenses as of December 31, 2016. For the year ended December 31, 2016, $679,000 and $460,000 are included in research and development expenses and general and administrative expenses, respectively. There was no expense recorded for the year ended December 31, 2017 in connection with this program. 2017 Incentive Bonus Program During 2017, our employees and executives are participating in the 2017 Incentive Bonus Program. The program provides for the award of quarterly and annual bonuses to our employees and executive officers if certain performance goals, based on company-wide billings, expenses and certain other individual non-monetary targets, are attained in quarterly and annual performance periods during our 2017 fiscal year. The awards contain a combination of service conditions and performance conditions based on the achievement of specified performance thresholds. The awards are based on each individual’s annual salary multiplied by a bonus multiplier percentage which has been determined by our compensation committee. The plan also allows for additional discretionary awards to non-executive employees up to 10% of the total base salaries of non-executive employees. Additionally, the annual bonus, as it relates to executive employees, is subject to the achievement of certain stock price thresholds for the 10 trading days ending on the last trading day of 2017. The bonuses may be paid in the form of cash, stock options, restricted stock, or a combination thereof. The number of shares underlying equity awards granted to each employee will be determined based on the performance bonus amount to be paid in equity, based in part by utilizing the stock price on the grant date. We recognize compensation expense for the total amount of the bonuses earned during the period earned. For the year ended December 31, 2017, we recorded a total of $1.5 million of expense related to the 2017 incentive bonus plan as the performance conditions were achieved. Included in the expense for 2017 is $670,000 related to quarterly awards which were paid in the form of stock options and restricted stock units and has been recorded as stock compensation expense. Of the total expense recorded for the year ended December 31, 2017, $916,000 is included in research and development expenses and $625,000 is included in general and administrative expenses. As of December 31, 2017 there was $695,000 included in accrued salaries and payroll related expenses for this program. 2017 Non-executive Bonus Program Effective July 1, 2017 , our non-executive employees participated in the 2017 Non-executive Bonus Program. The program provided for the award of up to 300,000 restricted stock units to be awarded to non-executive employees and consultants based upon the achievement of certain performance conditions before the end of the year. Vesting of the restricted stock units are subject to continued service over the vesting period. Based on the achievement of performance conditions, 180,528 restricted stock units were granted on January 25, 2018 . The awards will vest in four tranches with 25% of the shares vesting on each April 1, 2018, 2019, 2020 and 2021. We recorded $414,000 of stock compensation expense related to the 2017 Non-executive Bonus Program for the year ended December 31, 2017 of which $338,000 and $76,000 is included in research and development expenses and general and administrative expenses, respectively. Common Stock Issued to Non-Employees In February 2016, we issued 3,000 shares of our common stock to a consultant in exchange for employment recruiting services. In April 2016, we issued 5,549 shares of common stock to a previous employee in connection with a separation agreement. We recorded $6,000 in stock compensation expense related to the stock issuances for the year ended December 31, 2016. The amount of compensation expense related to the consultant shares issued represents the fair value of the stock on the dates of issuance. There was no expense recorded during the year ended December 31, 2016 related to the shares issued to our previous employee as the value of those shares had been accrued at the time of separation in 2015. Total equity-based compensation costs recorded in the consolidated statements of comprehensive loss is allocated as follows: Year Ended Year Ended December 31, 2017 Research and development Employees $ 944,000 $ 1,937,000 Non-employees 36,000 181,000 Total research and development 980,000 2,118,000 General and administrative Employees and directors 1,372,000 1,824,000 Non-employees 307,000 179,000 Total general and administrative 1,679,000 2,003,000 Total equity-based compensation 2,659,000 4,121,000

COMMITMENT AND CONTINGENCIES

COMMITMENT AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
COMMITMENT AND CONTINGENCIES	COMMITMENT AND CONTINGENCIES In October 2013, we signed a lease for office space for our corporate headquarters and moved into the new location in the first quarter of 2014. The lease had a term of 38 months and a rental cost of approximately $5,412 per month, increasing 3% annually after the first fourteen months . In addition, our share of building operating costs were estimated to be $2,101 per month. In April 2014, we amended the lease to add additional space which increased our rent to $8,286 per month beginning August 1, 2014 plus estimated monthly operating costs of $3,154 and extended the lease term through July, 2017. We had a renewal option for an additional 3 year term. The original lease included a tenant improvement allowance of $72,160 and the amended lease included an additional tenant improvement allowance of $38,320 . The allowances were used to construct our office build-out and have been capitalized as leasehold improvements as of December 31, 2016 and 2017 . The capitalized costs are being amortized over the amended lease term through July 2017. Effective April 2017, we amended the lease to add additional space and to extend our lease term through July 2018, with an option to extend through July, 2019. With the amendment, the total leased space is now 9,024 feet with monthly rent of $14,479 through July 31, 2017 and $13,987 from August 1, 2017 through the end of the lease, plus estimated monthly operating costs of approximately $7,000 . In November 2013, we signed a lease for our satellite development office in Burlingame, CA. The lease had a two -year term, and rental costs of approximately $4,000 per month. In May 2015, we renewed the lease for a one year period expiring November 30, 2016 with rental costs of $5,000 per month. Effective December 16, 2016, we signed a new lease of 5,248 square feet of office space within the same building in Burlingame, California commencing February 2017. The lease has a five -year term, and rental costs of approximately $17,000 per month. Rent expense related to our facilities was $220,000 and $477,000 , respectively, for the years ended December 31, 2016 and 2017 . Future minimum rent payments are as follows: Years ending December 31, 2018 $ 430,000 2019 $ 212,000 2020 $ 218,000 2021 $ 224,000 2022 $ 19,000 Total minimum rent payments $ 1,103,000 Legal Proceedings — W e are occasionally involved in legal proceedings and other matters arising from the normal course of business. Beginning on March 17, 2015, three putative class action lawsuits were filed in the United States District Court for the Central District of California, naming us, Terry Lingren and John Philpott as defendants. The three lawsuits were consolidated into a single putative class action, In re Resonant Inc. Securities Litigation, Case No. 15-cv-01970 SJO (MRWx). On February 23, 2016, the plaintiffs filed a consolidated second amended complaint, purporting to assert claims under the federal securities laws against us, Terry Lingren, John Philpott, and the underwriter of our May 29, 2014 IPO. In the consolidated second amended complaint, the plaintiffs purported to be acting on behalf of a class consisting of purchasers or acquirers of our common stock between November 6, 2014 and April 2, 2015, as well as a class of persons or entities who purchased or acquired our shares in (or traceable to) our IPO. The plaintiffs alleged that, as a result of the defendants’ allegedly false and/or misleading statements and/or omissions concerning our business, operations, prospects and performance, our common stock traded at artificially inflated prices between November 6, 2014 and April 2, 2015. On July 11, 2016, the court entered an order granting in part and denying in part our motion to dismiss the consolidated second amended complaint. The court granted the motion to dismiss with respect to plaintiffs’ claims under Section 11 of the Securities Act of 1933 and Section 20(a) of the Securities Exchange Act of 1934. The court also granted the motion to dismiss plaintiffs’ claims under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder to the extent those claims were premised on alleged misstatements made on February 26, 2015. The court denied the motion to dismiss with respect to plaintiffs’ claims under Section 15 of the Securities Act of 1933, and with respect to plaintiffs’ claims under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder to the extent those claims were premised on alleged misstatements made in November and December of 2014 and January of 2015. On October 26, 2016, the court issued an order clarifying its July 11, 2016 order on the motion to dismiss, making clear that the court's actual intent was to grant the motion to dismiss with respect to the claims under Section 15 of the Securities Act of 1933, while denying the motion to dismiss with respect to the claims under Section 20(a) of the Securities Exchange Act of 1934. On November 22, 2017, the court granted final approval of a settlement which fully resolved plaintiffs’ claims and provided for a release of all claims asserted in the class action litigation, bringing the litigation to a close. The settlement amount was paid by our insurance carrier. On September 24, 2015, a purported shareholder derivative action was filed in the United States District Court for the Central District of California, and is pending before the same federal district court judge to whom the putative class action was assigned. In the derivative action, the plaintiff alleges that certain of our officers and directors breached their fiduciary duties to us, including by allegedly violating the federal securities laws and exposing us to possible financial liability. The parties to the shareholder derivative action have reached a settlement that, if approved by the court, will fully resolve plaintiff’s claims and provide for the release of all claims asserted in the litigation. On February 1, 2018, the court entered an order granting preliminary approval of the settlement. The court has scheduled a final approval hearing to take place on April 2, 2018. We can make no assurances that the court will grant final approval of the settlement. We intend to continue to defend ourselves vigorously in these actions. We are not party to any other legal proceedings. We may, from time to time, be party to litigation and subject to claims incident to the ordinary course of business. As our growth continues, we may become party to an increasing number of litigation matters and claims. The outcome of litigation and claims cannot be predicted with certainty, and the resolution of any future matters could materially affect our future financial position, results of operations or cash flows. We have directors’ and officers’ liability insurance, which will be utilized in the defense of these matters. The liability insurance may not cover all of the future liabilities we may incur in connection with the foregoing matters. As of December 31, 2017 , we have incurred legal expenses of approximately $750,000 . Legal fees and other costs associated with such actions are expensed as incurred. We assess, in conjunction with our legal counsel, the need to record a liability for litigation and contingencies. Litigation accruals are recorded when and if it is determined that a loss related matter is both probable and reasonably estimable. Material loss contingencies that are reasonably possible of occurrence, if any, are subject to disclosure. Based on the very early stage of litigation for the cases referred to above, it is not possible to estimate the amount or range of possible loss that might result from an adverse judgment or a settlement of these matters. We will evaluate developments in legal proceedings and other matters on a quarterly basis. As of December 31, 2016 and 2017 , there was no litigation or contingency with at least a reasonable possibility of a material loss. No losses have been recorded during the years ended December 31, 2016 and 2017 , respectively, with respect to litigation or loss contingencies.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The benefit from income taxes by jurisdiction consist of the following for the years ended December 31, 2016 and 2017 : Year Ended December 31, 2016 Year Ended December 31, 2017 U.S. federal Current $ — $ — Deferred — — Total U.S. federal — — U.S. state and local Current 1,000 1,000 Deferred — — Total U.S. state and local 1,000 1,000 Foreign Current — — Deferred (23,000 ) (15,000 ) Total foreign (23,000 ) (15,000 ) Benefit from income taxes $ (22,000 ) $ (14,000 ) Income taxes differ from the amounts computed by applying the U.S. federal income tax rate to pretax income (loss) before income taxes as a result of the following for the years ended December 31, 2016 and 2017 : Year ended December 31, 2016 Year ended December 31, 2017 Expected income tax benefit $ (5,191,000 ) $ (7,357,000 ) State income tax (benefit), net of federal benefit (1,022,000 ) (1,176,000 ) Valuation allowance 6,219,000 7,398,000 Permanent differences: Stock options 173,000 95,000 Warrants — 914,000 Transaction costs 31,000 — Research & development credit (267,000 ) (263,000 ) Adjustment to deferred taxes (12,000 ) 267,000 Foreign rate differential 28,000 19,000 Other 19,000 89,000 Provision for (benefit from) for income taxes $ (22,000 ) $ (14,000 ) For year ended December 31, 2016 and 2017, we recorded a net income tax benefit of $22,000 and $14,000 , respectively, which included $1,000 and $1,000 of income tax expense offset by $23,000 and $15,000 , respectively, for the change in deferred foreign taxes. Deferred income tax reflects the tax effects of temporary differences that gave rise to significant portions of our deferred tax assets and liabilities. Deferred income taxes consisted of the following as of December 31, 2016 and 2017 : Year ended December 31, 2016 Year ended December 31, 2017 U.S. federal and state deferred tax assets—long term: Accrued payroll $ 525,000 $ 376,000 Accrued expenses — 21,000 Fixed assets 80,000 111,000 Intangibles 702,000 457,000 Research & development credit 1,257,000 1,464,000 Net operating loss 11,515,000 13,204,000 Stock compensation 772,000 539,000 New jobs credit 7,000 8,000 Total long-term assets 14,858,000 16,180,000 Total deferred tax assets 14,858,000 16,180,000 U.S. federal and state deferred tax liabilities—long term: Fixed assets — — Total deferred tax liabilities — — Net deferred tax assets - long term 14,858,000 16,180,000 Less: Valuation allowance (14,858,000 ) (16,180,000 ) Net deferred tax assets $ — $ — Foreign deferred tax assets—long term: Net operating loss $ 16,000 $ 12,000 Total foreign deferred tax assets 16,000 12,000 Foreign deferred tax liabilities—long term: Intangibles (32,000 ) (13,000 ) Total foreign deferred tax liabilities (32,000 ) (13,000 ) Net foreign deferred tax liabilities $ (16,000 ) $ (1,000 ) In December 2017, the Tax Cuts and Jobs Act (the “2017 Tax Act”) was enacted. The 2017 Tax Act represents major tax reform legislation that, among other provisions, reduced the U.S. corporate tax rate. The reduction in the tax rate reduced our federal and state net deferred tax assets by $6.1 million , primarily related to our net operating loss carryforwards. Due to the full valuation allowance recorded against our federal and state net deferred tax assets, there was no impact to our income tax expense for the year ended December 31, 2017 . We recorded a full valuation allowance against our U.S. federal and state net deferred tax assets at December 31, 2016 and December 31, 2017 . In determining the need for a valuation allowance, we reviewed all available evidence pursuant to the requirements of FASB ASC 740. Based upon our assessment of all available evidence, we have concluded that it is more likely than not that the net deferred tax assets will not be realized. For the year ended December 31, 2016 , the valuation allowance increased by $6.2 million . For the year ended December 31, 2017 , the valuation allowance increased by $1.3 million . As of December 31, 2017 , we had federal net operating loss carryforwards of approximately $47.0 million , state net operating loss carryforwards of approximately $46.9 million and foreign net operating loss carryforwards of $75,000 in Switzerland. The federal net operating loss carryforwards will begin to expire in 2033, and the state net operating loss carryforwards will begin to expire in 2033. Our ability to utilize net operating loss carryforwards may be limited in the event that a change in ownership, as defined in Section 382 of the Internal Revenue Code, occurs in the future. In the event a change of ownership occurs, it will limit the annual usage of the carryforwards in future years. Management believes that certain changes in control have occurred which resulted in limitations on our net operating loss carryforwards; however, management has determined that these limitations will not impact the ultimate utilization of the net operating loss carryforwards. We recognize interest and penalties related to income tax matters in income taxes, and there were none during the years ended December 31, 2016 and 2017 . The adoption of ASC 740 guidance required us to identify, evaluate and measure all uncertain tax positions taken or to be taken on tax returns and to record liabilities for the amount of these positions that may not be sustained, or may only partially be sustained, upon examination by the relevant taxing authorities. Although we believe that our estimates and judgments were reasonable, actual results may differ from these estimates. Some or all of these judgments are subject to review by the taxing authorities. We have no significant uncertain tax positions for the years ended December 31, 2016 and 2017 . Our annual income taxes and the determination of the resulting deferred tax assets and liabilities involve a significant amount of judgment. Our judgments, assumptions and estimates relative to current income taxes take into account current tax laws, their interpretation of current tax laws and possible outcomes of future audits conducted by domestic tax authorities. We operate within federal and state taxing jurisdictions and are subject to audit in these jurisdictions. These audits can involve complex issues which may require an extended period of time to resolve. We are currently not being examined by any tax authorities. We are subject to taxation in the United States, California, Massachusetts and Switzerland. As of December 31, 2017 , our tax years remain open to examination by the taxing authorities for all years since our incorporation in 2013.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS In August 2016, we entered into a consulting agreement with a member of our board of directors. Under the agreement, the board member would provide engineering design and fabrication advisory services for an hourly rate, with total payments not to exceed $120,000 during any twelve-month period. During the years ended December 31, 2016 and 2017, we incurred expenses of $42,000 and $26,000 , respectively, in connection with the consulting agreement. As of December 31, 2016, we owed $16,000 to the board member in connection with this agreement and it was paid in 2017. The agreement was terminated effective April 1, 2017.

EMPLOYEE BENEFIT PLAN

EMPLOYEE BENEFIT PLAN	12 Months Ended
	Dec. 31, 2017
Retirement Benefits [Abstract]
EMPLOYEE BENEFIT PLAN	EMPLOYEE BENEFIT PLAN We have a 401(k) Savings Retirement Plan that covers substantially all domestic employees who meet the plan’s eligibility requirements and provides for an employee elective contribution and employer matching contributions. We recorded matching contributions to the retirement plan of $204,000 and $284,000 for the years ended December 31, 2016 and 2017 , respectively.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS We evaluated subsequent events through February 27, 2018 , the date of issuance of the consolidated financial statements for the year ended December 31, 2017 .

SUMMARY OF SIGNIFICANT ACCOUN20

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates —The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. In the opinion of management, all adjustments (consisting of normal accruals) considered for a fair presentation have been included. Significant estimates made in preparing these financial statements include (a) assumptions to calculate the fair values of financial instruments, warrants and equity instruments and other liabilities and the deferred tax asset valuation allowance and (b) the useful lives for depreciable and amortizable assets. Actual results could differ from those estimates. In the opinion of management, all adjustments, including normal recurring accruals considered necessary for a fair presentation, have been included.
Consolidation	Consolidation - The accompanying financial statements include the accounts of the Company and its wholly-owned subsidiary, GVR Trade, S.A. All significant intercompany balances and transactions have been eliminated.
Cash and Cash Equivalents	Cash and Cash Equivalents —We consider all liquid instruments purchased with a maturity of three months or less to be cash equivalents.
Concentration of Credit Risk	Concentration of Credit Risk —We maintain checking accounts at one U.S. financial institution. The U.S. bank accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per account owner. GVR Trade S.A., our wholly owned Swiss-based subsidiary maintains checking accounts at one major national financial institution. Additionally, we maintain a checking account with a very minimal balance at one bank in South Korea, which is used to fund payroll and rent in South Korea. Management believes we are not exposed to significant credit risk due to the financial position of the depository institutions in which our deposits are held.
Restricted Cash	Restricted Cash —Restricted cash at December 31, 2016 and December 31, 2017 represents cash held within a certificate of deposit with a financial institution, which serves as collateral for our corporate credit cards. The restriction on the cash will lapse in conjunction with the expiration of the use of the corporate credit cards.
Investments	Investments —Securities held-to-maturity: Management determines the appropriate classification of debt securities at the time of purchase and reevaluates such designation as of each balance sheet date. Investment/debt securities are classified as held-to-maturity when we have the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest method. Such amortization is included in investment income. Interest on securities classified as held-to-maturity is included in investment income. When the fair value of an investment instrument classified as held-to-maturity is less than its amortized cost, management assesses whether or not: (i) we have the intent to sell the instrument or (ii) it is more likely than not that we will be required to sell the instrument before its anticipated recovery. If either of these conditions is met, we must recognize an other-than-temporary impairment for the difference between the instrument’s amortized cost basis and its fair value, and include such amounts in net securities gains (losses). For investment instruments that do not meet the above criteria and are not expected to be recovered at the amortized cost basis, the instrument is considered other-than-temporarily impaired. For these instruments, we separate the total impairment into the credit loss component and the amount of the loss related to other factors. In order to determine the amount of the credit loss, we calculate the recovery value by performing a discounted cash flow analysis based on the current cash flows and future cash flows management expects to recover. The discount rate is the effective interest rate implicit in the underlying instrument. The amount of the total other-than-temporary impairment related to credit loss is recognized in earnings and is included in net securities gains (losses). The amount of the total other-than-temporary impairment related to other factors is recognized in other comprehensive income. For investment instruments that have other-than-temporary impairment recognized through earnings, if through subsequent evaluation there is a significant increase in the cash flow expected, the difference between the amortized cost basis and the cash flows expected to be collected is accreted as interest income. During 2016, we invested in corporate paper and federally insured certificates of deposit that we have classified as held-to-maturity. As of December 31, 2016, the amortized cost value was $4.7 million with an unrealized loss of $2,000 and a fair value of $4.7 million . The investments consisted of $4.0 million of corporate paper, of which $3.0 million matured in January of 2017 and $1.0 million matured in February of 2017, and $747,000 of certificates of deposit which matured in increments of $249,000 between January and March of 2017. We did not recognize an other-than-temporary impairment gain or loss or a comprehensive gain or loss as of December 31, 2016. During 2017, we invested in commercial papers and certificates of deposit that were classified as investments held-to-maturity. Additionally, we maintained money market fund balances that were classified as cash and cash equivalents. As of December 31, 2017, all of our investments held-to-maturity have matured and we have no investments classified as held-to-maturity. We recorded investment income of $22,000 and $67,000 for the years ended December 31, 2016 and 2017, respectively, associated with our cash and investment accounts.
Fair Value of Financial Instruments	Fair Value of Financial Instruments —We measure certain financial assets and liabilities at fair value based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The carrying amounts of our financial instruments, including cash equivalents, restricted cash, investments held-to-maturity, accounts payable, and accrued liabilities, approximate fair value due to their short maturities.
Accounts Receivable	Accounts Receivable —Trade accounts receivable are stated net of allowances for doubtful accounts. Management estimates the allowance for doubtful accounts based on review and analysis of specific customer balances that may not be collectible, customer payment history and any other customer-specific information that may impact collectability of the receivable. Accounts are considered for write-off when they become past due and when it is determined that the probability of collection is remote. The was no allowance for doubtful accounts at December 31, 2016 and December 31, 2017.
Property and Equipment	Property and Equipment —Property and equipment consists of leasehold improvements associated with our corporate offices, software purchased during the normal course of business, equipment and office furniture and fixtures, all of which are recorded at cost. During 2016, other property and equipment were acquired as part of the purchase of GVR and were initially recorded at their fair value. Depreciation and amortization is recorded using the straight-line method over the respective useful lives of the assets ranging from three to five years . Leasehold improvements are amortized over the shorter of lease term or useful life. Long-lived assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable.
Intangible Assets, net	Intangible Assets, net —Intangible assets are recorded at cost and amortized over the useful life. In the case of business combinations, intangible assets are recorded at fair value. At December 31, 2016 and December 31, 2017 , intangible assets, net, includes patents, domain name and other intangibles purchased from GVR, including customer relationships, technology and trademark. Intangible assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable.
Goodwill	Goodwill— At December 31, 2017 , goodwill represents the difference between the price paid to acquire GVR Trade and the fair value of the assets acquired, net of assumed liabilities. We review goodwill for impairment annually and whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable.
Revenue Recognition	Revenue Recognition —Revenue consists primarily of fees received in connection with filter design projects with customers. Contracts may involve upfront non-refundable fees, intended to support our initial engineering product development efforts, as well as milestone payments based upon the successful completion of certain deliverables. In relation to the upfront non-refundable fees, we recognize revenue in accordance with the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 605, Revenue Recognition. We recognize revenue as the services are performed over the initial engineering filter design development period and when all of the following criteria have been met: persuasive evidence of an arrangement exists, services have been rendered, collection of the revenue is reasonably assured, and the fees are fixed or determinable. We record the expenses related to these projects in the periods incurred and they are generally included in research and development expense. In addition to the upfront non-refundable payments, the filter design projects include certain milestone payments upon successful filter design or a design stage completion. These filter design projects are associated with complex technology development, and as such we do not have certainty about our ability to achieve the program milestones. Achievement of the milestone is generally dependent on the filter design specifications and the milestone typically needs to be accepted by the customer. The payment associated with achieving the milestone is generally commensurate with our effort or the value of the deliverable and is generally non-refundable. We record revenue associated with the milestone payments in accordance with ASC Topic 605-28, Milestone Method, whereby we record revenue upon successful completion of the related milestone and when collection of the revenue is reasonably assured. We record the expenses related to these projects, generally included in research and development expense, in the periods incurred.
Research and Development	Research and Development —Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with ASC Topic 730-10, Research and Development .
Operating Leases	Operating Leases —We lease office space and research facilities under operating leases. Certain lease agreements contain free or escalating rent payment provisions. We recognize rent expense under such leases on a straight-line basis over the term of the lease. Lease renewal periods are considered on a lease-by-lease basis in determining the lease term.
Stock-Based Compensation	Stock-Based Compensation —We account for employee stock options in accordance with ASC Topic 718, Compensation-Stock Compensation . For stock options issued to employees and directors we use the Black-Scholes option valuation model for estimating fair value at the date of grant. For stock options issued for services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC Topic 505-50 , Equity , or ASC 505-50, as amended. Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to performance, the value of these options, as calculated using the Black-Scholes option valuation model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options or warrants are fully vested. We account for restricted stock units issued to employees at fair value, based on the market price of our stock on the date of grant, net of estimated forfeitures. Compensation expense is recognized for the portion of the award that is ultimately expected to vest over the period during which the recipient renders the required services to the Company generally using the straight-line single option method. The fair value of non-employee restricted stock units awarded are remeasured as the awards vest, and the resulting increase or decrease in fair value, if any, is recognized as an increase or decrease to compensation expense in the period the related services are rendered. In the case of award modifications, we account for the modification by recognizing the effect of the modification in the period the award was modified. Stock-based compensation expense is included in research and development expenses and general and administrative expenses.
Earnings Per Share, or EPS	Earnings Per Share, or EPS —EPS is computed in accordance with ASC Topic 260, Earnings per Share , and is calculated using the weighted average number of common shares outstanding during each period. Diluted EPS assumes the conversion, exercise or issuance of all potential common stock equivalents unless the effect is to reduce a loss or increase the income per share. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options (using the treasury stock method), the exercise of warrants (using the if-converted method) and the vesting of restricted stock unit awards.
Income Taxes	Income Taxes —We account for income taxes in accordance with ASC Topic 740, Income Taxes , or ASC 740, which requires the recognition of deferred tax assets and liabilities for the future consequences of events that have been recognized in our condensed consolidated financial statements or tax returns. The measurement of the deferred items is based on enacted tax laws. In the event the future consequences of differences between financial reporting bases and the tax bases of our assets and liabilities result in a deferred tax asset, ASC 740 requires an evaluation of the probability of being able to realize the future benefits indicated by such asset. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion or the entire deferred tax asset will not be realized. As part of the process of preparing our consolidated financial statements, we are required to estimate our income tax expense in each of the jurisdictions in which we operate. We also assess temporary differences resulting from differing treatment of items for tax and accounting differences. We record a valuation allowance to reduce the deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. For the period when we were organized as a limited liability company, we were treated as a partnership for federal and state income tax purposes under the entity classification domestic default rules. As of December 31, 2016 and December 31, 2017 , no liability for unrecognized tax benefits was required to be reported. We recognize interest and penalties related to income tax matters in income taxes, and there were none for the years ended December 31, 2016 and December 31, 2017 , respectively. We have filed, or are in the process of filing, tax returns that are subject to audit by the respective tax authorities. Although the ultimate outcome would be unknown, we believe that any adjustments that may result from tax return audits are not likely to have a material, adverse effect on our consolidated results of operations, financial position or cash flows.
Reclassifications	Reclassifications —Certain amounts in the consolidated statement of operations for the year ended December 31, 2016 have been reclassified to conform to the current year presentation.
Business Combinations	Business Combinations— We record business combinations using the acquisition method of accounting and, accordingly, allocate the fair value of purchase consideration to the assets acquired and liabilities assumed based on their fair values at the acquisition date. The excess of the fair value of the purchase consideration over the fair value of the assets acquired and liabilities assumed is recorded as goodwill. The results of operations of the business acquired are included in our consolidated results of operations beginning on the date of acquisition.
Foreign Currency Transaction	Foreign Currency Translation —The Swiss Franc has been determined to be the functional currency for the net assets of our Swiss-based subsidiary. We translate the assets and liabilities to U.S. dollars at each reporting period using exchange rates in effect at the balance sheet date and record the effects of the foreign currency translation in accumulated other comprehensive income (loss) in shareholders' equity. We translate the income and expenses to U.S. dollars at each reporting period using the average exchange rate in effect for the period and record the effects of the foreign currency translation as other comprehensive income (loss) in the consolidated statements of comprehensive loss. Gains and losses resulting from foreign currency transactions are included in net loss in the consolidated statements of comprehensive loss.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Revenue from Contracts with Customers— In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) . The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date , which defers the effective date of ASU No. 2014-09 for all entities by one year to annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. This ASU shall be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. Early adoption is permitted but not before the annual periods beginning after December 15, 2016, including interim periods within that reporting period. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net) . This ASU provides further guidance surrounding the recognition of revenue as well as guidance involving principal versus agent considerations. The effective date of this ASU is the same as ASU 2014-09. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing . This amendment provides clarification surrounding the identification of performance obligations and offers licensing implementation guidance. The effective date of this ASU is the same as ASU 2014-09. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606), Narrow-Scope Improvements and Practical Expedients, which provides further guidance surrounding certain aspects of ASU 2014-09. The effective date of this ASU is the same as ASU 2014-09. The new standards became effective for us on January 1, 2018 and we adopted at that time using the modified retrospective approach with a cumulative adjustment to reflect the initial impact recognized at the date of adoption. We believe the impact is not significant due to the relatively small number of contracts and nature of our contracts, which are primarily related to design development projects where the revenue is recognized over time under both the prior guidance and the new revenue recognition standard. We believe the adoption of the new standard will result in an increase to contract assets and a corresponding increase to retained earnings. The impact of the adoption is primarily related to the recognition of income from milestones within our contracts. Up until January 1, 2018, we recognized income related to milestones at the time when the milestone was achieved. Under the new guidance we are required to estimate the likelihood of such achievement, and recognize the income over the period of achievement. Leases— In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , a comprehensive new leases standard that amends various aspects of existing accounting guidance for leases. It will require recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The main difference between previous U.S. GAAP and the amended standard is the recognition of lease assets and lease liabilities by lessees on the balance sheet for those leases classified as operating leases under previous U.S. GAAP. The accounting applied by a lessor is largely unchanged from that applied under previous U.S. GAAP. As a result, we will have to recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing our right to use the underlying asset for the lease term on the balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. We are currently reviewing the two leases we have and are evaluating the effects of the new guidance on our consolidated financial statements. We do not expect it to have a material impact on our consolidated financial statements. Intangibles-Goodwill and Other— In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , which simplifies the accounting for goodwill impairments by eliminating step 2 from the goodwill impairment test. The amended guidance will become effective for us commencing in the first quarter of fiscal 2019. We are currently evaluating the impact of this new standard. Compensation-Stock Compensation— In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting , which provides clarity over the accounting for a change to the terms or conditions of a share-based payment award. The amendments in the update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. The amendments in this update should be applied prospectively to an award modification on or after the adoption date. This guidance became effective for us on January 1, 2018 and will be applied to all future share-based award modifications.

SUMMARY OF SIGNIFICANT ACCOUN21

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of number of anti-dilutive shares excluded from the calculation of diluted net loss per share attributable to common stockholders	The following table presents the number of shares excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods below: Year Ended December 31, 2016 Year Ended December 31, 2017 Common stock warrants 2,915,559 3,730,255 Common stock options 801,690 1,082,490 Non-vested restricted stock unit awards 1,455,558 1,476,858 Total shares excluded from net loss per share attributable to common stockholders 5,172,807 6,289,603

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL (Tables)	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Intangible assets consisted of the following at December 31, 2016 and 2017 : 2016 2017 Patents $ 1,132,000 $ 1,349,000 Domain Name 22,000 22,000 Client Base (1) 137,000 143,000 Trademark (1) 17,000 17,000 Backlog (1) 12,000 13,000 Technology 84,000 77,000 1,404,000 1,621,000 Less: accumulated amortization (151,000 ) (268,000 ) Net intangible assets $ 1,253,000 $ 1,353,000 (1) Includes the impact of foreign currency translation. The total impact at December 31, 2016 was $5,000 and the total impact at December 31, 2017 was $2,000 .
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Amortization of intangible assets was $89,000 and $126,000 for the years ended December 31, 2016 and 2017 , respectively. The following table summarizes the estimated amortization expense relating to the intangible assets as of December 31, 2017 : Years ending December 31, 2018 $ 130,000 2019 103,000 2020 76,000 2021 66,000 2022 56,000 2023 and thereafter 418,000 Total amortization expense $ 849,000
Schedule of Goodwill	Goodwill is not amortized, but is subject to impairment tests on at least an annual basis and whenever circumstances suggest that goodwill may be impaired. Goodwill Balance at January 1, 2016 $ — Acquisition of GVR 824,000 Effect of currency translation (35,000 ) Balance at December 31, 2016 $ 789,000 Effect of currency translation $ 35,000 Balance at December 31, 2017 $ 824,000

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Schedule of property and equipment, net	Property and equipment, net consists of the following: 2016 2017 Cost: Computers, peripheral and scientific equipment $ 618,000 $ 1,016,000 Software 967,000 1,367,000 Leasehold Improvements 470,000 502,000 Office furniture and equipment 214,000 327,000 2,269,000 3,212,000 Less accumulated depreciation and amortization (1,275,000 ) (1,858,000 ) Property and equipment, net $ 994,000 $ 1,354,000

ACQUISITION OF GVR TRADE S.A. (

ACQUISITION OF GVR TRADE S.A. (Tables)	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The purchase price was allocated based on the fair values of assets and liabilities as follows: Assets acquired Cash and cash equivalents $ 148,000 Other current assets 52,000 Property and equipment 23,000 Intangible assets Customer relationships 143,000 Developed technology 88,000 Trademarks and other 31,000 Total assets acquired 485,000 Liabilities assumed Current liabilities (35,000 ) Deferred tax liability (41,000 ) Deferred revenue, current (27,000 ) Total liabilities assumed (103,000 ) Net value of assets acquired and liabilities assumed 382,000 Total purchase price 1,206,000 Excess of purchase price over fair value of assets acquired and liabilities assumed - recorded as Goodwill $ 824,000

WARRANTS (Tables)

WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2017
Warrants and Rights Note Disclosure [Abstract]
Schedule of warrant activity	A roll-forward of warrant activity from January 1, 2016 to December 31, 2016 is shown in the following table: Issued and Warrants Warrants Issued and Bridge Warrants 249,999 — — 249,999 Consulting Warrant 117,778 — (19,778 ) (1) 98,000 Financing Warrants 78,186 — — 78,186 Underwriting Warrant 310,500 — — 310,500 IR Consulting Warrants 48,000 — — 48,000 Private Placement Warrants - 2016 — 2,096,724 (101,600 ) (2) 1,995,124 Underwriting Warrants - Public Offering 2016 — 135,750 — 135,750 804,463 2,232,474 (121,378 ) 2,915,559 (1) During the year ended December 31, 2016, there were 19,778 common stock warrants that were exercised through a cashless exercise which netted 19,693 shares being issued. (2) During the year ended December 31, 2016, there were 3,600 common stock warrants that were exercised through a cashless exercise which netted 1,375 shares being issued. Additionally, there were 98,000 warrants exercised for cash. A roll-forward of warrant activity from January 1, 2017 to December 31, 2017 is shown in the following table: Issued and Warrants Warrants Issued and Bridge Warrants 249,999 — — 249,999 Consulting Warrant 98,000 — (85,777 ) (1 ) 12,223 Financing Warrants 78,186 — (15,656 ) (2 ) 62,530 Underwriting Warrant 310,500 — — 310,500 IR Consulting Warrants 48,000 — (42,000 ) (3 ) 6,000 Private Placement Warrants - 2016 1,995,124 — (1,104,061 ) (4 ) 891,063 Underwriting Warrants - Public Offering 2016 135,750 — (13,575 ) (5 ) 122,175 Private Placement Warrants - February 2017 — 1,626,898 (1,626,898 ) (6 ) — Private Placement Warrants - September 2017 — 1,976,919 — 1,976,919 Placement Agent Warrants - 2017 — 98,846 — 98,846 2,915,559 3,702,663 (2,887,967 ) 3,730,255 (1) During the year ended December 31, 2017, there were 85,777 common stock warrants that were exercised through cashless exercises which netted 85,620 shares being issued. (2) During the year ended December 31, 2017, there were 15,656 common stock warrants that were exercised through a cashless exercise which netted 6,842 shares being issued. (3) During the year ended December 31, 2017, 42,000 warrants expired. (4) During the year ended December 31, 2017, there were 122,281 common stock warrants that were exercised through cashless exercises which netted 49,063 shares being issued. Additionally, there were 981,780 warrants that were exercised for cash, which included 836,780 warrants exercised subject to inducement, which offered the warrant holder an inducement fee of $0.29 /share to exercise the warrant in full for cash immediately. (5) During the year ended December 31, 2017, there were 13,575 common stock warrants that were exercised through a cashless exercise which netted 6,322 shares being issued. (6) During the year ended December 31, 2017, there were 1,626,898 common stock warrants that were exercised for cash. The warrants were exercised subject to inducement, which offered the warrant holder an inducement fee of $4.13 /share to exercise the warrant in full for cash immediately.

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of fair values of stock options granted, estimated using Black-Scholes option valuation model assumptions	The fair values of stock options granted for the years were estimated using the following assumptions: Option Grants Awarded During the Year Ended December 31, 2016 Option Grants Awarded During the Year Ended December 31, 2017 Stock Price $1.93 - $5.50 $4.36 - $7.80 Dividend Yield 0% 0% Expected Volatility 60.0% 60.0% Risk-free interest rate 1.30% - 2.06% 1.95% - 2.37% Expected Term 7 years 7 to 10years
Summary of stock option activity	The following is a summary of our stock option activity during the year ended December 31, 2016 : Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Outstanding, January 1, 2016 565,050 $ 6.57 $ 4.25 7.84 Granted 346,500 3.03 1.81 8.51 Exercised — — — — Canceled/Forfeited (109,860 ) 5.08 3.32 — Outstanding, December 31, 2016 801,690 $ 5.25 $ 3.32 7.40 Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Exercisable, January 1, 2016 302,415 $ 6.25 $ 4.11 7.07 Vested 173,010 5.37 3.43 5.95 Exercised — — — — Canceled/Forfeited (56,251 ) 5.87 3.87 — Exercisable, December 31, 2016 419,174 $ 5.94 $ 3.86 6.00 The following is a summary of our stock option activity during the year ended December 31, 2017 : Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Outstanding, January 1, 2017 801,690 $ 5.25 $ 3.32 7.40 Granted 488,300 4.62 2.79 9.51 Exercised (32,928 ) 2.37 1.41 — Canceled/Forfeited (174,572 ) 6.4 4.18 — Outstanding, December 31, 2017 1,082,490 $ 4.87 $ 3.00 8.38 Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Exercisable, January 1, 2017 419,174 5.94 3.86 6.00 Vested 457,338 4.57 2.77 8.65 Exercised (32,928 ) 2.37 1.41 — Canceled/Forfeited (139,281 ) 6.65 4.38 — Exercisable, December 31, 2017 704,303 5.08 3.17 8.15
Schedule of information related to stock options outstanding and exercisable	The following table presents information related to stock options outstanding and exercisable at December 31, 2017 : Options Outstanding Options Exercisable Exercise Price Outstanding Number of Options Weighted Average Remaining Life In Years Exercisable Number of Options $1.93 - $2.00 149,000 8.10 65,198 $3.83 - $4.70 523,190 9.38 343,198 $5.06 - $6.00 250,000 6.67 197,199 $6.18 – $7.20 70,000 6.67 40,945 $7.54 – $7.80 67,800 6.96 41,817 $8.06 - $12.98 22,500 7.04 15,946 1,082,490 8.15 704,303
Schedule of Share-based Compensation, Restricted Stock Units Award Activity	A summary of restricted stock unit activity for the year ended December 31, 2016 is as follows: Number of Restricted Share Units Weighted-Average Grant-Date Fair Value Per Share Outstanding at January 1, 2016 375,629 $ 6.16 Granted 1,383,159 3.22 Vested (262,201 ) 4.54 Forfeited (41,029 ) 5.64 Outstanding at December 31, 2016 1,455,558 $ 3.64 A summary of restricted stock unit activity for the year ended December 31, 2017 is as follows: Number of Restricted Share Units Weighted-Average Grant-Date Fair Value Per Share Outstanding at January 1, 2017 1,455,558 $ 3.64 Granted 722,400 5.37 Vested (649,359 ) 4.26 Forfeited (51,741 ) 5.40 Outstanding at December 31, 2017 1,476,858 $ 4.96
Schedule of stock-based compensation	Total equity-based compensation costs recorded in the consolidated statements of comprehensive loss is allocated as follows: Year Ended Year Ended December 31, 2017 Research and development Employees $ 944,000 $ 1,937,000 Non-employees 36,000 181,000 Total research and development 980,000 2,118,000 General and administrative Employees and directors 1,372,000 1,824,000 Non-employees 307,000 179,000 Total general and administrative 1,679,000 2,003,000 Total equity-based compensation 2,659,000 4,121,000

COMMITMENT AND CONTINGENCIES (T

COMMITMENT AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum lease payments under operating leases	Future minimum rent payments are as follows: Years ending December 31, 2018 $ 430,000 2019 $ 212,000 2020 $ 218,000 2021 $ 224,000 2022 $ 19,000 Total minimum rent payments $ 1,103,000

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of income taxes by jurisdiction	The benefit from income taxes by jurisdiction consist of the following for the years ended December 31, 2016 and 2017 : Year Ended December 31, 2016 Year Ended December 31, 2017 U.S. federal Current $ — $ — Deferred — — Total U.S. federal — — U.S. state and local Current 1,000 1,000 Deferred — — Total U.S. state and local 1,000 1,000 Foreign Current — — Deferred (23,000 ) (15,000 ) Total foreign (23,000 ) (15,000 ) Benefit from income taxes $ (22,000 ) $ (14,000 )
Schedule of income taxes differ from the amounts computed by applying the U.S. federal income tax rate to pretax income (loss) before income taxes	ncome taxes differ from the amounts computed by applying the U.S. federal income tax rate to pretax income (loss) before income taxes as a result of the following for the years ended December 31, 2016 and 2017 : Year ended December 31, 2016 Year ended December 31, 2017 Expected income tax benefit $ (5,191,000 ) $ (7,357,000 ) State income tax (benefit), net of federal benefit (1,022,000 ) (1,176,000 ) Valuation allowance 6,219,000 7,398,000 Permanent differences: Stock options 173,000 95,000 Warrants — 914,000 Transaction costs 31,000 — Research & development credit (267,000 ) (263,000 ) Adjustment to deferred taxes (12,000 ) 267,000 Foreign rate differential 28,000 19,000 Other 19,000 89,000 Provision for (benefit from) for income taxes $ (22,000 ) $ (14,000 )
Schedule of components of deferred income tax	Deferred income taxes consisted of the following as of December 31, 2016 and 2017 : Year ended December 31, 2016 Year ended December 31, 2017 U.S. federal and state deferred tax assets—long term: Accrued payroll $ 525,000 $ 376,000 Accrued expenses — 21,000 Fixed assets 80,000 111,000 Intangibles 702,000 457,000 Research & development credit 1,257,000 1,464,000 Net operating loss 11,515,000 13,204,000 Stock compensation 772,000 539,000 New jobs credit 7,000 8,000 Total long-term assets 14,858,000 16,180,000 Total deferred tax assets 14,858,000 16,180,000 U.S. federal and state deferred tax liabilities—long term: Fixed assets — — Total deferred tax liabilities — — Net deferred tax assets - long term 14,858,000 16,180,000 Less: Valuation allowance (14,858,000 ) (16,180,000 ) Net deferred tax assets $ — $ — Foreign deferred tax assets—long term: Net operating loss $ 16,000 $ 12,000 Total foreign deferred tax assets 16,000 12,000 Foreign deferred tax liabilities—long term: Intangibles (32,000 ) (13,000 ) Total foreign deferred tax liabilities (32,000 ) (13,000 ) Net foreign deferred tax liabilities $ (16,000 ) $ (1,000 )

ORGANIZATION AND DESCRIPTION 29

ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Accumulated deficit	$ (67,812,000)	$ (46,159,000)
Existing cash balances and investments	19,500,000
Cash used in operating activities	15,600,000
Maximum aggregate proceeds from public offerings	35,000,000
Sales of common stock, net of offering costs	15,950,000	$ 15,798,000
Capital Units
Class of Stock [Line Items]
Sales of common stock, net of offering costs	$ 11,500,000
Sales of common stock, net of offering costs (in shares)	2,715
Securities available for issuance	$ 23,500,000

SUMMARY OF SIGNIFICANT ACCOUN30

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	12 Months Ended
	Dec. 31, 2017USD ($)financial_institution	Dec. 31, 2016USD ($)
Debt Instrument [Line Items]
Investment held-to-maturity	$ 0	$ 4,747,000
Deferred Revenue, Revenue Recognized	$ 653,000	302,000
Number of financial institutions | financial_institution	1
Held-to-maturity Securities [Abstract]
Unrecognized holding loss		2,000
Fair value of debt securities		4,700,000
Investment income	$ 67,000	22,000
Income Taxes
Unrecognized tax benefits	0	0
Income tax penalties and interest expense	$ 0	0
Minimum
Property and Equipment
Useful lives	3 years
Maximum
Property and Equipment
Useful lives	5 years
Commercial Paper
Debt Instrument [Line Items]
Investment held-to-maturity		4,000,000
Commercial Paper | Commercial Paper, Maturing January 2017
Debt Instrument [Line Items]
Investment held-to-maturity		3,000,000
Commercial Paper | Commercial Paper, Maturing February 2017
Debt Instrument [Line Items]
Investment held-to-maturity		1,000,000
Debt Securities | Certificates of Deposit
Debt Instrument [Line Items]
Investment held-to-maturity		747,000
Debt Securities | Certificates of Deposit | Certificate of Deposit, Maturing January 2017
Held-to-maturity Securities [Abstract]
Fair value of debt securities	$ 200,000	$ 249,000
Debt Securities | Certificates of Deposit | Certificate of Deposit, Maturing February 2017
Held-to-maturity Securities [Abstract]
Fair value of debt securities	200,000
Debt Securities | Certificates of Deposit | Certificate of Deposit, Maturing March 2017
Held-to-maturity Securities [Abstract]
Fair value of debt securities	200,000
Development of Filter Designs
Held-to-maturity Securities [Abstract]
Deferred revenue	$ 143,000

SUMMARY OF SIGNIFICANT ACCOUN31

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Anti-dilutive Shares Excluded from EPS) (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from net loss per share attributable to common stockholders	6,289,603	5,172,807
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from net loss per share attributable to common stockholders	3,730,255	2,915,559
Non-vested restricted stock unit awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from net loss per share attributable to common stockholders	1,082,490	801,690
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from net loss per share attributable to common stockholders	1,476,858	1,455,558

INTANGIBLE ASSETS AND GOODWIL32

INTANGIBLE ASSETS AND GOODWILL (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Write-off of abandoned patents	$ 8	$ 19
Amortization of intangible assets	$ 126	$ 89
Patents | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life	17 years
Patents | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life	20 years
STI | Patents | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life	1 year
STI | Patents | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life	12 years
STI | Domain Name
Finite-Lived Intangible Assets [Line Items]
Useful life	10 years
GVR Trade S.A. | Patents | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life	3 years
GVR Trade S.A. | Patents | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life	5 years

INTANGIBLE ASSETS AND GOODWIL33

INTANGIBLE ASSETS AND GOODWILL (Intangible Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	$ 1,621	$ 1,404
Less: accumulated amortization	(268)	(151)
Net intangible assets	1,353	1,253
Impact of foreign currency translation	2	5
Patents
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	1,349	1,132
Domain Name
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	22	22
Client Base
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	143	137
Trademark
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	17	17
Backlog
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	13	12
Technology
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	$ 77	$ 84

INTANGIBLE ASSETS AND GOODWIL34

INTANGIBLE ASSETS AND GOODWILL (Schedule of Future Amortization Expense) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Net intangible assets	$ 1,353	$ 1,253
Intangible Assets, Excluding Pending Patents
Finite-Lived Intangible Assets [Line Items]
2,018	130
2,019	103
2,020	76
2,021	66
2,022	56
2023 and thereafter	418
Net intangible assets	$ 849

INTANGIBLE ASSETS AND GOODWIL35

INTANGIBLE ASSETS AND GOODWILL (Goodwill) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Goodwill [Roll Forward]
Balance at the beginning of the period	$ 789	$ 0
Acquisitions		824
Effect of currency translation	35	(35)
Balance at the end of the period	$ 824	$ 789

PROPERTY AND EQUIPMENT, NET (De

PROPERTY AND EQUIPMENT, NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property and equipment, gross	$ 3,212	$ 2,269
Less: Accumulated depreciation and amortization	(1,858)	(1,275)
PROPERTY AND EQUIPMENT, NET	1,354	994
Depreciation	594	604
Property disposed of	21	1
Computers, peripheral and scientific equipment
Property and equipment, gross	1,016	618
Software
Property and equipment, gross	1,367	967
Leasehold Improvements
Property and equipment, gross	502	470
Office furniture and equipment
Property and equipment, gross	$ 327	$ 214

ACQUISITION OF GVR TRADE S.A.37

ACQUISITION OF GVR TRADE S.A. (Narrative) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	Jul. 06, 2016	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill acquired			$ 824
GVR Trade S.A.
Business Acquisition [Line Items]
Payments to acquire business	$ 661
Equity interests issued, value	$ 545
Per share price (in dollars per share)	$ 4.36
Consideration transferred	$ 1,200
Acquisition related costs		$ 92
Goodwill acquired	$ 824
Comprehensive net loss		$ 58	$ 127
Common Stock | GVR Trade S.A.
Business Acquisition [Line Items]
Equity interest issues, number of shares	125

ACQUISITION OF GVR TRADE S.A.38

ACQUISITION OF GVR TRADE S.A. (Schedule of Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Jul. 06, 2016	Dec. 31, 2015
Liabilities assumed
Excess of purchase price over fair value of assets acquired and liabilities assumed - recorded as Goodwill	$ 824	$ 789		$ 0
GVR Trade S.A.
Assets acquired
Cash and cash equivalents			$ 148
Other current assets			52
Property and equipment			23
Intangible assets
Customer relationships			143
Developed technology			88
Trademarks and other			31
Total assets acquired			485
Liabilities assumed
Current liabilities			(35)
Deferred tax liability			(41)
Deferred revenue, current			(27)
Total liabilities assumed			(103)
Net value of assets acquired and liabilities assumed			382
Total purchase price			1,206
Excess of purchase price over fair value of assets acquired and liabilities assumed - recorded as Goodwill			$ 824

WARRANTS (Narrative) (Details)

WARRANTS (Narrative) (Details)

Dec. 31, 2017USD ($)$ / sharesshares

Dec. 19, 2017USD ($)$ / sharesshares

Dec. 18, 2017USD ($)$ / shares

Oct. 02, 2017shares

Sep. 28, 2017USD ($)$ / sharesshares

Feb. 22, 2017$ / sharesshares

Sep. 14, 2016USD ($)$ / sharesshares

Apr. 25, 2016USD ($)$ / sharesshares

Jun. 17, 2013USD ($)$ / sharesshares

Dec. 31, 2017USD ($)$ / sharesshares

Sep. 30, 2017USD ($)$ / shares

Feb. 28, 2017USD ($)$ / sharesshares

Sep. 30, 2016$ / sharesshares

Apr. 30, 2016shares

Oct. 31, 2014$ / sharesshares

Aug. 31, 2014$ / sharesshares

Mar. 31, 2013$ / sharesshares

Jan. 31, 2013tranchefounder$ / sharesshares

Oct. 31, 2017$ / sharesshares

Mar. 31, 2013USD ($)$ / sharesshares

Sep. 30, 2017USD ($)$ / shares

Sep. 30, 2016USD ($)$ / sharesshares

Dec. 31, 2017USD ($)$ / sharesshares

Dec. 31, 2016USD ($)shares

Mar. 19, 2013shares

Warrant liabilities

Sales of common stock, net of offering costs | $

$ 15,950,000

$ 15,798,000

Proceeds from exercise of warrants | $

9,272,000

280,000

Non-cash warrant inducement expense | $

2,688,000

0

Capital Units

Warrant liabilities

Sales of common stock, net of offering costs | $

$ 11,500,000

Assumptions used in estimating fair value of warrants

Sales of common stock, net of offering costs (in shares)

2,715,000

Common Stock

Warrant liabilities

Sales of common stock, net of offering costs | $

$ 4,000

$ 5,000

Assumptions used in estimating fair value of warrants

Implied unit price/stock price (in dollars per unit/share) | $ / shares

$ 8.25

$ 4.25

Sales of common stock, net of offering costs (in shares)

1

1

2,715,000

3,603,817

4,711,880

Exercise of warrants, cashless (in shares)

147,847

21,068

Founders | Class B Member’s | Resonant LLC

Warrant liabilities

Warrants to purchase shares of common stock or units (in units/shares)

124,998

Investors, Executives and Board Members | Capital Units

Warrant liabilities

Sales of common stock, net of offering costs | $

$ 5,200,000

Assumptions used in estimating fair value of warrants

Implied unit price/stock price (in dollars per unit/share) | $ / shares

$ 2.985

Sales of common stock, net of offering costs (in shares)

1,996,880

Investors, Executives and Board Members | Common stock warrants

Warrant liabilities

Sales of common stock, net of offering costs | $

$ 10,600,000

Placement agents

Assumptions used in estimating fair value of warrants

Equity value | $

$ 200,000

Implied unit price/stock price (in dollars per unit/share) | $ / shares

$ 4.85

Placement agents | Capital Units

Assumptions used in estimating fair value of warrants

Implied unit price/stock price (in dollars per unit/share) | $ / shares

$ 4.85

$ 2.86

Sales of common stock, net of offering costs (in shares)

99,844

Placement agents | Common Stock

Assumptions used in estimating fair value of warrants

Sales of common stock, net of offering costs (in shares)

135,750

Period end after closing

2 years

Placement agents | Private Placement, Offering One

Assumptions used in estimating fair value of warrants

Partners' Capital Account, Units, Sold in Private Placement

87,279

Placement agents | Private Placement, Offering Two

Assumptions used in estimating fair value of warrants

Partners' Capital Account, Units, Sold in Private Placement

11,567

Placement agents | Private Placement, Offering Two | Common stock warrants

Assumptions used in estimating fair value of warrants

Partners' Capital Account, Units, Sold in Private Placement

98,846

Bridge Warrants | Resonant LLC

Warrant liabilities

Number of tranches in which warrants were issued | tranche

2

Proceeds from exercise of warrants | $

$ 1,000

Bridge Warrants | Founders

Warrant liabilities

Warrant term

5 years

5 years

Exercise price (in dollars per unit/share) | $ / shares

$ 0.20

$ 0.4

$ 0.4

Warrants to purchase shares of common stock or units (in units/shares)

249,999

Bridge warrants issued in January 2013

Warrant liabilities

Warrants to purchase shares of common stock or units (in units/shares)

20,833

20,833

20,833

Bridge warrants issued in January 2013 | Class B Member’s | Resonant LLC

Warrant liabilities

Warrants to purchase shares of common stock or units (in units/shares)

62,499

62,499

Consulting Warrant

Assumptions used in estimating fair value of warrants

Exercise of warrants, cashless (in shares)

85,620

19,693

Consulting warrants issued in October 2014 | IR Consultant

Warrant liabilities

Warrant term

4 years

Exercise price (in dollars per unit/share) | $ / shares

$ 6.50

Warrants to purchase shares of common stock or units (in units/shares)

6,000

Financing Warrants

Assumptions used in estimating fair value of warrants

Exercise of warrants, cashless (in shares)

6,842

Private Placement Warrants

Warrant liabilities

Sales of common stock, net of offering costs | $

$ 2,400,000

Proceeds from exercise of warrants | $

2,200,000

Non-cash warrant inducement expense | $

$ 239,000

Assumptions used in estimating fair value of warrants

Equity value | $

$ 2,500,000

Implied unit price/stock price (in dollars per unit/share) | $ / shares

$ 2.90

$ 2.90

Expected volatility (as a percent)

60.00%

Expected dividend rate (as a percent)

0.00%

Risk free interest rate (as a percent)

0.97%

Expected Life

3 years

Exercise of warrants, cashless (in shares)

49,063

1,375

Private Placement Warrants | Private Placement

Warrant liabilities

Warrants to purchase shares of common stock or units (in units/shares)

836,780

836,780

1,996,880

836,780

Private Placement Warrants | Common Stock

Warrant liabilities

Fair value adjustment of warrants | $

$ 166,000

Inducement expense after fair value adjustment | $

$ 73,000

Assumptions used in estimating fair value of warrants

Equity value | $

$ 3,800,000

$ 3,900,000

Expected volatility (as a percent)

60.00%

10.00%

Expected dividend rate (as a percent)

0.00%

Risk free interest rate (as a percent)

2.00%

Expected Life

1 day

1 year 5 months 1 day

Private Placement Warrants | Minimum | Common Stock

Assumptions used in estimating fair value of warrants

Exercise price (in dollars per unit/share) | $ / shares

$ 6.96

$ 6.96

$ 6.96

Risk free interest rate (as a percent)

1.00%

2.00%

Private Placement Warrants | Maximum | Common Stock

Assumptions used in estimating fair value of warrants

Exercise price (in dollars per unit/share) | $ / shares

$ 7.42

$ 7.42

7.42

Risk free interest rate (as a percent)

1.00%

2.00%

Private Placement Warrants | Investors, Executives and Board Members

Warrant liabilities

Exercise price (in dollars per unit/share) | $ / shares

$ 2.86

$ 2.86

$ 2.86

$ 2.86

Assumptions used in estimating fair value of warrants

Period start after closing

6 months

Period end after closing

36 months

Private Placement Warrants | Investors, Executives and Board Members | Private Placement

Assumptions used in estimating fair value of warrants

Sales of common stock, net of offering costs (in shares)

1,996,880

Private Placement Warrants | Placement agents

Assumptions used in estimating fair value of warrants

Implied unit price/stock price (in dollars per unit/share) | $ / shares

$ 2.86

Sales of common stock, net of offering costs (in shares)

99,844

836,780

Underwriting Warrant

Assumptions used in estimating fair value of warrants

Expected volatility (as a percent)

60.00%

Sales of common stock, net of offering costs (in shares)

1,976,919

Underwriting Warrant | Common Stock

Warrant liabilities

Warrants to purchase shares of common stock or units (in units/shares)

2,715,000

2,715,000

Assumptions used in estimating fair value of warrants

Equity value | $

$ 475,000

Implied unit price/stock price (in dollars per unit/share) | $ / shares

$ 6.54

$ 6.54

Expected volatility (as a percent)

60.00%

Risk free interest rate (as a percent)

0.90%

Expected Life

3 years

Underwriting Warrant | Minimum

Assumptions used in estimating fair value of warrants

Implied unit price/stock price (in dollars per unit/share) | $ / shares

$ 4.49

Risk free interest rate (as a percent)

1.59%

Underwriting Warrant | Maximum

Assumptions used in estimating fair value of warrants

Implied unit price/stock price (in dollars per unit/share) | $ / shares

$ 4.69

Risk free interest rate (as a percent)

1.63%

Underwriting Warrant | Investors, Executives and Board Members

Warrant liabilities

Exercise price (in dollars per unit/share) | $ / shares

$ 4.25

$ 4.25

Underwriting Warrant | Investors, Executives and Board Members | Private Placement

Assumptions used in estimating fair value of warrants

Sales of common stock, net of offering costs (in shares)

135,750

Underwriting Warrant | Placement agents

Assumptions used in estimating fair value of warrants

Sales of common stock, net of offering costs (in shares)

98,846

Private Placement Warrants - February 2017

Warrant liabilities

Proceeds from exercise of warrants | $

$ 6,700,000

Fair value adjustment of warrants | $

4,100,000

Non-cash warrant inducement expense | $

6,700,000

Inducement expense after fair value adjustment | $

2,600,000

Assumptions used in estimating fair value of warrants

Equity value | $

$ 13,400,000

$ 4,100,000

Implied unit price/stock price (in dollars per unit/share) | $ / shares

$ 8.18

$ 8.18

Expected volatility (as a percent)

10.00%

Risk free interest rate (as a percent)

1.25%

Expected Life

1 year 8 months 1 day

Private Placement Warrants - February 2017 | Private Placement

Warrant liabilities

Warrants to purchase shares of common stock or units (in units/shares)

1,626,898

1,626,898

Assumptions used in estimating fair value of warrants

Period end after closing

30 months

Private Placement Warrants - February 2017 | Investors, Executives and Board Members

Warrant liabilities

Exercise price (in dollars per unit/share) | $ / shares

$ 8.25

Private Placement Warrants - February 2017 | Investors, Executives and Board Members | Common Stock

Warrant liabilities

Exercise price (in dollars per unit/share) | $ / shares

$ 8.25

Private Placement Warrants - February 2017 | Individual Investor | Private Placement

Assumptions used in estimating fair value of warrants

Sales of common stock, net of offering costs (in shares)

1,626,898

Private Placement Warrants - February 2017 | Individual Investor | Private Placement | Capital Units

Assumptions used in estimating fair value of warrants

Sales of common stock, net of offering costs (in shares)

1,626,898

Private Placement Warrants, February 2017, After Modifications

Assumptions used in estimating fair value of warrants

Equity value | $

$ 6,700,000

Private Placement Warrants - September 2017

Assumptions used in estimating fair value of warrants

Equity value | $

$ 3,600,000

Private Placement Warrants - September 2017 | Private Placement

Warrant liabilities

Warrants to purchase shares of common stock or units (in units/shares)

231,338

1,745,581

1,976,919

Assumptions used in estimating fair value of warrants

Period start after closing

6 months

Period end after closing

36 months

Private Placement Warrants - September 2017 | Minimum

Assumptions used in estimating fair value of warrants

Implied unit price/stock price (in dollars per unit/share) | $ / shares

$ 4.49

$ 4.49

Risk free interest rate (as a percent)

1.59%

Private Placement Warrants - September 2017 | Maximum

Assumptions used in estimating fair value of warrants

Implied unit price/stock price (in dollars per unit/share) | $ / shares

$ 4.69

$ 4.69

Risk free interest rate (as a percent)

1.63%

Private Placement Warrants - September 2017 | Investors, Executives and Board Members | Capital Units

Warrant liabilities

Exercise price (in dollars per unit/share) | $ / shares

$ 4.85

Private Placement Warrants - September 2017 | Investors, Executives and Board Members | Private Placement | Capital Units

Assumptions used in estimating fair value of warrants

Sales of common stock, net of offering costs (in shares)

1,976,919

MDB | Consulting Warrant

Warrant liabilities

Warrant term

7 years

Exercise price (in dollars per unit/share) | $ / shares

$ 0.01

Warrants to purchase shares of common stock or units (in units/shares)

222,222

Assumptions used in estimating fair value of warrants

Value of shares of common stock divided by exercise price of warrant's to determine exercisable warrants | $

$ 700,000

MDB | Financing Warrants

Warrant liabilities

Warrant term

7 years

MDB | Underwriting Warrant

Warrant liabilities

Warrant term

5 years

Exercise price (in dollars per unit/share) | $ / shares

$ 7.50

Warrants to purchase shares of common stock or units (in units/shares)

310,500

Warrants exercisable period from underwriting agreement

180 days

IR Firm | Consulting warrants issued in August 2014

Warrant liabilities

Number of founders | founder

3

Warrant term

3 years

Exercise price (in dollars per unit/share) | $ / shares

$ 0.40

Warrants to purchase shares of common stock or units (in units/shares)

42,000

Assumptions used in estimating fair value of warrants

Exercise price (in dollars per unit/share) | $ / shares

$ 8.31

IR Firm | Private Placement Warrants - February 2017

Assumptions used in estimating fair value of warrants

Equity value | $

$ 2,100,000

Implied unit price/stock price (in dollars per unit/share) | $ / shares

$ 4.91

Risk free interest rate (as a percent)

1.50%

Expected Life

3 years

WARRANTS (Schedule of Warrant A

WARRANTS (Schedule of Warrant Activity) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Roll forward of warrant activity
Balance at the beginning of the period	2,915,559	804,463
Warrants Issued	3,702,663	2,232,474
Warrant Exercised/Expired	(2,887,967)	(121,378)
Balance at the end of the period	3,730,255	2,915,559
Bridge Warrants
Roll forward of warrant activity
Balance at the beginning of the period	249,999	249,999
Balance at the end of the period	249,999	249,999
Consulting Warrant
Roll forward of warrant activity
Balance at the beginning of the period	98,000	117,778
Warrant Exercised/Expired	(85,777)	(19,778)
Balance at the end of the period	12,223	98,000
Exercise of warrants, cashless (in shares)	85,620	19,693
Financing Warrants
Roll forward of warrant activity
Balance at the beginning of the period	78,186	78,186
Warrant Exercised/Expired	(15,656)
Balance at the end of the period	62,530	78,186
Exercise of warrants, cashless (in shares)	6,842
Financing Warrants | Cashless
Roll forward of warrant activity
Warrant Exercised/Expired	(15,656)
Underwriting Warrant
Roll forward of warrant activity
Balance at the beginning of the period	310,500	310,500
Warrant Exercised/Expired	0
Balance at the end of the period	310,500	310,500
IR Consulting Warrants
Roll forward of warrant activity
Balance at the beginning of the period	48,000	48,000
Warrant Exercised/Expired	(42,000)
Balance at the end of the period	6,000	48,000
Private Placement Warrants - 2016
Roll forward of warrant activity
Balance at the beginning of the period	1,995,124	0
Warrants Issued		2,096,724
Warrant Exercised/Expired	(1,104,061)	(101,600)
Balance at the end of the period	891,063	1,995,124
Exercise of warrants, cashless (in shares)	49,063	1,375
Private Placement Warrants - 2016 | Cashless
Roll forward of warrant activity
Warrant Exercised/Expired	(122,281)	(3,600)
Private Placement Warrants - 2016 | Cash
Roll forward of warrant activity
Warrant Exercised/Expired	(981,780)	(98,000)
Warrant exercised, subject to inducement (in shares)	836,780
Inducement, fee amount (in dollars per share)	$ 0.29
Underwriting Warrants - Public Offering 2016
Roll forward of warrant activity
Balance at the beginning of the period	135,750	0
Warrants Issued		135,750
Warrant Exercised/Expired	(13,575)
Balance at the end of the period	122,175	135,750
Exercise of warrants, cashless (in shares)	6,322
Private Placement Warrants - February 2017
Roll forward of warrant activity
Warrants Issued	1,626,898
Warrant Exercised/Expired	(1,626,898)
Balance at the end of the period	0
Private Placement Warrants - February 2017 | Cash
Roll forward of warrant activity
Warrant Exercised/Expired	(1,626,898)
Inducement, fee amount (in dollars per share)	$ 4.13
Private Placement Warrants - September 2017
Roll forward of warrant activity
Warrants Issued	1,976,919
Warrant Exercised/Expired	0
Balance at the end of the period	1,976,919
Placement Agent Warrants - 2017
Roll forward of warrant activity
Warrants Issued	98,846
Warrant Exercised/Expired	0
Balance at the end of the period	98,846

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details) - USD ($)	Oct. 02, 2017	Sep. 28, 2017	Feb. 22, 2017	Sep. 14, 2016	Apr. 25, 2016	Dec. 31, 2017	Apr. 30, 2016	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Class of Stock [Line Items]
Common stock, shares authorized						47,000,000		47,000,000	47,000,000
Class of Warrant or Right, Outstanding						3,730,255		3,730,255	2,915,559		804,463
Net proceeds from the sale of common stock from private placement offerings								$ 15,950,000	$ 5,177,000
Legal Fees			$ 29,000					750,000
Sales of common stock, net of offering costs								15,950,000	$ 15,798,000
Maximum aggregate proceeds from public offerings						$ 35,000,000		$ 35,000,000
Preferred stock, shares authorized						3,000,000		3,000,000	3,000,000
Placement agents
Class of Stock [Line Items]
Share price (in dollars per share)		$ 4.85
Capital Units
Class of Stock [Line Items]
Sales of common stock, net of offering costs (in shares)								2,715,000
Sales of common stock, net of offering costs								$ 11,500,000
Securities available for issuance						$ 23,500,000		$ 23,500,000
Capital Units | Investors, Executives and Board Members
Class of Stock [Line Items]
Sales of common stock, net of offering costs (in shares)					1,996,880
Share price (in dollars per share)					$ 2.985
Net proceeds from the sale of common stock from private placement offerings					$ 6,000,000
Sales of common stock, net of offering costs					$ 5,200,000
Capital Units | Institutional and Individual Investors
Class of Stock [Line Items]
Share price (in dollars per share)	$ 4.85	4.70	$ 4.61
Capital Units | Placement agents
Class of Stock [Line Items]
Sales of common stock, net of offering costs (in shares)					99,844
Share price (in dollars per share)		$ 4.85			$ 2.86
Common Stock
Class of Stock [Line Items]
Sales of common stock, net of offering costs (in shares)	1		1	2,715,000				3,603,817	4,711,880
Share price (in dollars per share)			$ 8.25	$ 4.25
Sales of common stock, net of offering costs								$ 4,000	$ 5,000
Common Stock | Placement agents
Class of Stock [Line Items]
Sales of common stock, net of offering costs (in shares)				135,750
Investment warrants, exercise price				$ 4.25
Period end after closing								2 years
Common stock warrants
Class of Stock [Line Items]
Class of Warrant or Right, Outstanding	1		1
Net proceeds from the sale of common stock from private placement offerings				$ 11,500,000
Common stock warrants | Investors, Executives and Board Members
Class of Stock [Line Items]
Investment warrants, exercise price					$ 2.86
Sales of common stock, net of offering costs				$ 10,600,000
Common stock warrants | Institutional and Individual Investors
Class of Stock [Line Items]
Period start after closing		6 months	6 months
Period end after closing		36 months	30 months
Private Placement, Offering Two | Placement agents
Class of Stock [Line Items]
Partners' Capital Account, Units, Sold in Private Placement		11,567
Private Placement, Offering Two | Capital Units | Institutional and Individual Investors
Class of Stock [Line Items]
Net proceeds from the sale of common stock from private placement offerings	$ 1,100,000	$ 8,200,000	$ 7,500,000
Proceeds from Issuance of Private Placement, Net of Offering Costs	$ 1,000,000	$ 7,500,000
Partners' Capital Account, Units, Sold in Private Placement	231,338
Private Placement, Offering Two | Common stock warrants | Placement agents
Class of Stock [Line Items]
Partners' Capital Account, Units, Sold in Private Placement	98,846
Private Placement Warrants
Class of Stock [Line Items]
Share price (in dollars per share)										$ 2.90
Class of Warrant or Right, Outstanding						891,063		891,063	1,995,124		0
Sales of common stock, net of offering costs						$ 2,400,000
Private Placement Warrants | Investors, Executives and Board Members
Class of Stock [Line Items]
Period start after closing					6 months
Period end after closing					36 months
Private Placement Warrants | Placement agents
Class of Stock [Line Items]
Sales of common stock, net of offering costs (in shares)					99,844	836,780
Share price (in dollars per share)					$ 2.86
Private Placement Warrants | Private Placement | Investors, Executives and Board Members
Class of Stock [Line Items]
Sales of common stock, net of offering costs (in shares)							1,996,880
Private Placement Warrants | Private Placement | Capital Units | Institutional and Individual Investors
Class of Stock [Line Items]
Sales of common stock, net of offering costs (in shares)	1,976,919	1,745,581	1,626,898

STOCK-BASED COMPENSATION (Narra

STOCK-BASED COMPENSATION (Narrative) (Details)

Sep. 30, 2019

Aug. 08, 2016

Jun. 30, 2017shares

Feb. 28, 2017USD ($)$ / sharesshares

Jan. 31, 2017shares

Aug. 31, 2016shares

Jun. 30, 2016shares

Feb. 29, 2016shares

Dec. 31, 2017USD ($)item$ / sharesshares

Dec. 31, 2017USD ($)item$ / sharesshares

Dec. 31, 2016USD ($)$ / sharesshares

Dec. 31, 2015USD ($)

Jul. 01, 2017shares

Apr. 30, 2016shares

Dec. 31, 2014shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted Average Remaining Life In Years

8 years 1 month 24 days

6 years

7 years 26 days

Granted (in shares) | shares

488,300

346,500

Grant date fair value

$ 1,363,000

$ 627,000

Unrecognized compensation expense related to unvested employee stock option

$ 5,000,000

$ 5,000,000

Compensation cost not yet recognized, period for recognition

2 years 4 months 17 days

Number of shares vested in the period | shares

457,338

173,010

Number of grants in the period, weighted average exercise price | $ / shares

$ 4.62

$ 3.03

Shares issued to consultants | shares

19,511,276

19,511,276

12,468,647

Non-vested restricted stock unit awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted Average Remaining Life In Years

8 years 1 month 24 days

Granted (in shares) | shares

488,300

346,500

Number of quarter over which awards vest from grant date subsequent to initial vesting | item

16

16

Stock compensation expense

$ 435,000

$ 529,000

Unrecognized compensation expense related to unvested employee stock option

$ 925,000

925,000

Options outstanding, aggregate intrinsic value

2,892,000

2,892,000

647,000

Options vested, aggregate intrinsic value

$ 1,732,000

$ 1,732,000

$ 146,000

Share price (in dollars per share) | $ / shares

$ 7.47

$ 7.47

$ 5.05

Expected Volatility

60.00%

60.00%

Non-vested restricted stock unit awards | Minimum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share price (in dollars per share) | $ / shares

4.36

$ 4.36

$ 1.93

Risk-free interest rate

1.95%

1.30%

Expected Life

7 years

7 years

Non-vested restricted stock unit awards | Maximum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share price (in dollars per share) | $ / shares

$ 7.8

$ 7.8

$ 5.50

Dividend Yield

0.00%

0.00%

Risk-free interest rate

2.37%

2.06%

Expected Life

10 years

7 years

Restricted stock units

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted (in dollars per share) | $ / shares

$ 5.37

$ 3.22

Stock compensation expense

$ 2,600,000

$ 1,700,000

Granted (in shares) | shares

722,400

1,383,159

Vested (in shares) | shares

(649,359)

(262,201)

Number of shares forfeited in period | shares

51,741

41,029

2014 Omnibus Incentive Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares of common stock approved for issuance | shares

5,950,000

1,400,000

Number of additional shares authorized | shares

3,250,000

1,300,000

2014 Omnibus Incentive Plan | Non-vested restricted stock unit awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Term of award

10 years

10 years

2014 Omnibus Incentive Plan | Non-vested restricted stock unit awards | Minimum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise price range, lower limit (in dollars per share) | $ / shares

$ 4.36

$ 1.93

2014 Omnibus Incentive Plan | Non-vested restricted stock unit awards | Maximum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise price range, upper limit (in dollars per share) | $ / shares

$ 7.80

$ 5.50

2015 Performance Plan | Performance Based Awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock compensation expense

$ 121,000

Employees | Non-vested restricted stock unit awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Forfeitures rate

6.00%

Consultants

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted Average Remaining Life In Years

10 years

Consultants | Non-vested restricted stock unit awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock compensation expense

$ 9,000

$ 27,000

Non-executive employees | Performance Based Awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Bonus percentage

10.00%

Non-executive employees | 2015 Performance Plan | Performance Based Awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Bonus percentage

10.00%

Non-executive employees | 2017 Non-executive Bonus Program | Restricted stock units

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares of common stock approved for issuance | shares

300,000

Granted (in shares) | shares

180,528

Award vesting rights, percentage

25.00%

Stock compensation expense

$ 414,000

Executive employees | Non-vested restricted stock unit awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Accelerated vesting, number (in shares) | shares

8,752

26,876

Option exercise period extended, number (in shares) | shares

17,504

43,438

Plan modification, incremental compensation cost

19,000

$ 48,000

Executive employees | Performance Based Awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Award vesting rights, percentage

50.00%

Granted (in shares) | shares

250,000

Executive employees | Performance Based Awards | Maximum | Forecast

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Award vesting rights, percentage

50.00%

Common Stock | 2015 Performance Plan | Restricted stock units

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted (in shares) | shares

90,265

Number of shares vested in the period | shares

45,140

Common Stock | 2015 Performance Plan | Performance Based Awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock compensation expense

0

$ 44,000

Common Stock | 2016 Performance Plan | Non-vested restricted stock unit awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted (in shares) | shares

125,880

Common Stock | 2016 Performance Plan | Restricted stock units

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Grant date fair value

$ 119,000

Granted (in dollars per share) | $ / shares

$ 4.36

Granted (in shares) | shares

27,390

Common Stock | 2016 Performance Plan | Performance Based Awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Grant date fair value

$ 332,000

Aggregate grant date fair value of options granted

688,000

Stock compensation expense

$ 688,000

451,000

Weighted average closing price, number of consecutive trading days

10 days

Vesting period

10 days

Share price (in dollars per share) | $ / shares

$ 4.36

Dividend Yield

0.00%

Expected Volatility

60.00%

Risk-free interest rate

2.15%

Expected Life

7 years

Common Stock | 2016 Performance Plan | Performance Based Awards | Accrued Salaries And Payroll Related Expenses

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock compensation expense

1,100,000

Common Stock | 2016 Performance Plan | Performance Based Awards | Research and development

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock compensation expense

679,000

Common Stock | 2016 Performance Plan | Performance Based Awards | General and administrative

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock compensation expense

460,000

Common Stock | 2017 Incentive Bonus Program | Performance Based Awards | Research and development

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock compensation expense

916,000

Common Stock | 2017 Incentive Bonus Program | Performance Based Awards | General and administrative

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock compensation expense

625,000

Common Stock | 2017 Non-executive Bonus Program | Restricted stock units | Research and development

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock compensation expense

338,000

Common Stock | 2017 Non-executive Bonus Program | Restricted stock units | General and administrative

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock compensation expense

76,000

Common Stock | Employees

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares issued to consultants | shares

5,549

Common Stock | Consultants

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock compensation expense

6,000

Shares issued to consultants | shares

3,000

Common Stock | Executive employees

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock compensation expense

$ 670,000

1,500,000

Employee-related Liabilities

695,000

695,000

Common Stock | Executive employees | 2015 Performance Plan | Performance Based Awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Fair value of award

74,000

Stock compensation expense

24,000

$ 8,000

Compensation cost not yet recognized

$ 41,000

$ 41,000

Vesting period

1 year 9 months

Common Stock | Executive employees | 2017 Incentive Bonus Program | Performance Based Awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

10 days

STOCK-BASED COMPENSATION (Estim

STOCK-BASED COMPENSATION (Estimated Fair Value of Stock Options) (Details) - Non-vested restricted stock unit awards - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share)	$ 7.47	$ 5.05
Expected Volatility	60.00%	60.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share)	$ 4.36	$ 1.93
Risk-free interest rate	1.95%	1.30%
Expected Life	7 years	7 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share)	$ 7.8	$ 5.50
Dividend Yield	0.00%	0.00%
Risk-free interest rate	2.37%	2.06%
Expected Life	10 years	7 years

STOCK-BASED COMPENSATION (Stock

STOCK-BASED COMPENSATION (Stock Option Award Activity) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Number of Options outstanding
Outstanding at the beginning of the year (in shares)	801,690	565,050
Granted (in shares)	488,300	346,500
Exercised (in shares)	(32,928)
Forfeited (in shares)	(174,572)	(109,860)
Outstanding at the end of the reporting period (in shares)	1,082,490	801,690	565,050
Number of Options Exercisable
Exercisable at the beginning of the year (in shares)	419,174	302,415
Vested (in shares)	(457,338)	(173,010)
Forfeited (in shares)	(139,281)	(56,251)
Exercisable at the end of the reporting period (in shares)	704,303	419,174	302,415
Weighted Average Exercise Price Outstanding
Outstanding at the beginning of period (in dollars per share)	$ 5.25	$ 6.57
Granted (in dollars per share)	4.62	3.03
Exercised (in dollars per share)	2.37
Forfeited (in dollars per share)	6.40	5.08
Outstanding at the end of the reporting period (in dollars per share)	4.87	5.25	$ 6.57
Weighted Average Exercise Price Exercisable
Exercisable at the beginning of the reporting period (in dollars per share)	5.94	6.25
Vested exercisable (in dollars per share)	4.57	5.37
Canceled/Forfeited	6.65	5.87
Exercisable at the end of the reporting period (in dollars per share)	5.08	5.94	6.25
Weighted Average Grant Date Fair Value Outstanding
Outstanding at the beginning of the reporting period (in dollars per share)	3.32	4.25
Options granted (in dollars per share)	$ 2.79	1.81
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 1.41
Forfeited (in dollars per share)	$ 4.18	3.32
Outstanding at the end of the reporting period (in dollars per share)	3	3.32	4.25
Weighted Average Grant Date Fair Value Exercisable
Exercisable at the beginning of the reporting period (in dollars per share)	3.86	4.11
Vested options exercisable (in dollars per share)	2.77	3.43
Forfeited options exercisable (in dollars per share)	4.38	3.87
Exercisable at the end of the reporting period (in dollars per share)	$ 3.17	$ 3.86	$ 4.11
Weighted Average Remaining Life In Years Outstanding
Outstanding at the end of the reporting period (in years)	8 years 4 months 17 days	7 years 4 months 24 days	7 years 10 months 2 days
Granted, Weighted average remaining life (in years)	9 years 6 months 4 days	8 years 6 months 4 days
Weighted Average Remaining Life Exercisable
Exercisable at the end of the reporting period (in years)	8 years 1 month 24 days	6 years	7 years 26 days
Vested, Weighted average remaining live (in years)	8 years 7 months 24 days	5 years 11 months 12 days
Non-vested restricted stock unit awards
Number of Options outstanding
Granted (in shares)	488,300	346,500
Outstanding at the end of the reporting period (in shares)	1,082,490
Number of Options Exercisable
Exercisable at the end of the reporting period (in shares)	704,303
Weighted Average Remaining Life Exercisable
Exercisable at the end of the reporting period (in years)	8 years 1 month 24 days

STOCK-BASED COMPENSATION (Sto45

STOCK-BASED COMPENSATION (Stock Options Outstanding and Exercisable) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested restricted stock unit awards	1,082,490	801,690	565,050
Weighted Average Remaining Life In Years	8 years 1 month 24 days	6 years	7 years 26 days
Exercisable Number of Options	704,303	419,174	302,415
Non-vested restricted stock unit awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested restricted stock unit awards	1,082,490
Weighted Average Remaining Life In Years	8 years 1 month 24 days
Exercisable Number of Options	704,303
Non-vested restricted stock unit awards | $1.93 - $2.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested restricted stock unit awards	149,000
Weighted Average Remaining Life In Years	8 years 1 month 6 days
Exercisable Number of Options	65,198
Non-vested restricted stock unit awards | $3.83 - $4.70
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested restricted stock unit awards	523,190
Weighted Average Remaining Life In Years	9 years 4 months 17 days
Exercisable Number of Options	343,198
Non-vested restricted stock unit awards | $5.06 - $6.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested restricted stock unit awards	250,000
Weighted Average Remaining Life In Years	6 years 8 months 1 day
Exercisable Number of Options	197,199
Non-vested restricted stock unit awards | $6.18 – $7.20
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested restricted stock unit awards	70,000
Weighted Average Remaining Life In Years	6 years 8 months 1 day
Exercisable Number of Options	40,945
Non-vested restricted stock unit awards | $7.54 – $7.80
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested restricted stock unit awards	67,800
Weighted Average Remaining Life In Years	6 years 11 months 16 days
Exercisable Number of Options	41,817
Non-vested restricted stock unit awards | $8.06 - $12.98
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested restricted stock unit awards	22,500
Weighted Average Remaining Life In Years	7 years 15 days
Exercisable Number of Options	15,946
Non-vested restricted stock unit awards | Minimum | $1.93 - $2.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	$ 1.93
Non-vested restricted stock unit awards | Minimum | $3.83 - $4.70
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	3.83
Non-vested restricted stock unit awards | Minimum | $5.06 - $6.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	5.06
Non-vested restricted stock unit awards | Minimum | $6.18 – $7.20
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	6.18
Non-vested restricted stock unit awards | Minimum | $7.54 – $7.80
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	7.54
Non-vested restricted stock unit awards | Minimum | $8.06 - $12.98
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	8.06
Non-vested restricted stock unit awards | Maximum | $1.93 - $2.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	2
Non-vested restricted stock unit awards | Maximum | $3.83 - $4.70
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	4.70
Non-vested restricted stock unit awards | Maximum | $5.06 - $6.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	6
Non-vested restricted stock unit awards | Maximum | $6.18 – $7.20
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	7.20
Non-vested restricted stock unit awards | Maximum | $7.54 – $7.80
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	7.80
Non-vested restricted stock unit awards | Maximum | $8.06 - $12.98
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	$ 12.98

STOCK-BASED COMPENSATION (Restr

STOCK-BASED COMPENSATION (Restricted Stock Activity) (Details) - Restricted stock units - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Restricted Share Units
Outstanding at beginning of year (in shares)	1,455,558	375,629
Granted (in shares)	722,400	1,383,159
Vested (in shares)	(649,359)	(262,201)
Canceled (in shares)	(51,741)	(41,029)
Outstanding at end of year (in shares)	1,476,858	1,455,558
Restricted Share Weighted Average Grant Date Fair Value
Outstanding at beginning of year (in dollars per share)	$ 3.64	$ 6.16
Granted (in dollars per share)	5.37	3.22
Vested (in dollars per share)	4.26	4.54
Canceled (in dollars per share)	5.40	5.64
Outstanding at end of year (in dollars per share)	$ 4.96	$ 3.64

STOCK-BASED COMPENSATION (Equit

STOCK-BASED COMPENSATION (Equity Based Compensation Schedule) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Allocation of stock-based compensation expense
Stock compensation expense	$ 4,121	$ 2,659
Research and development
Allocation of stock-based compensation expense
Stock compensation expense	2,118	980
Research and development | Employees
Allocation of stock-based compensation expense
Stock compensation expense	1,937	944
Research and development | Non-employees
Allocation of stock-based compensation expense
Stock compensation expense	181	36
General and administrative
Allocation of stock-based compensation expense
Stock compensation expense	2,003	1,679
General and administrative | Non-employees
Allocation of stock-based compensation expense
Stock compensation expense	179	307
General and administrative | Employees and directors
Allocation of stock-based compensation expense
Stock compensation expense	$ 1,824	$ 1,372

COMMITMENT AND CONTINGENCIES (N

COMMITMENT AND CONTINGENCIES (Narrative) (Details)

Aug. 01, 2017USD ($)

Apr. 01, 2017USD ($)ft²

Mar. 17, 2017lawsuit

Feb. 22, 2017USD ($)

Dec. 16, 2016USD ($)ft²

Aug. 01, 2014USD ($)

May 30, 2015

Apr. 30, 2014

Nov. 30, 2013USD ($)

Oct. 31, 2013USD ($)

Dec. 31, 2017USD ($)

Dec. 31, 2016USD ($)

Operating Leases

Number of class action lawsuits | lawsuit

3

Tenant improvement allowance

$ 72,160

Additional tenant improvement allowance

38,320

Legal Proceedings

Legal fees

$ 29,000

$ 750,000

Loss contingency accrual

0

0

Loss in period

0

$ 0

Corporate Headquarters

Operating Leases

Term of lease

38 months

Renewal term of the lease

3 years

Square feet of office space | ft²

9,024

Monthly rental payments

$ 13,987

$ 14,479

$ 8,286

$ 5,412

Increase in rental payments (as a percent)

3.00%

Period after which monthly rental increases

14 months

Monthly operating cost

$ 7,000

$ 3,154

$ 2,101

Satellite development office

Operating Leases

Term of lease

1 year

2 years

Renewal term of the lease

5 years

Square feet of office space | ft²

5,248

Monthly rental payments

$ 17,000

$ 4,000

$ 5,000

COMMITMENT AND CONTINGENCIES (F

COMMITMENT AND CONTINGENCIES (Future Minimum Lease Payments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 477	$ 220
Future minimum lease payments
2,018	430
2,019	212
2,020	218
2,021	224
2,022	19
Total minimum rent payments	$ 1,103

INCOME TAXES (Income Taxes by J

INCOME TAXES (Income Taxes by Jurisdiction) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
U.S. federal
Current	$ 0	$ 0
Deferred	0	0
Total U.S. federal	0	0
U.S. state and local
Current	1	1
Deferred	0	0
Total U.S. state and local	1	1
Foreign
Current	0	0
Deferred	(15)	(23)
Total foreign	15	23
Income taxes differ from the amounts computed by applying the U.S. federal income tax rate to pretax income (loss) before income taxes
Expected income tax benefit	(7,357)	(5,191)
State income tax (benefit), net of federal benefit	(1,176)	(1,022)
Valuation allowance	7,398	6,219
Permanent differences:
Stock options	95	173
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Warrants	914	0
Transaction costs	0	31
Research & development credit	(263)	(267)
Adjustment to deferred taxes	267	(12)
Foreign rate differential	19	28
Other	89	19
Provision for (benefit from) income taxes	$ (14)	$ (22)

INCOME TAXES (Deferred Tax Asse

INCOME TAXES (Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
U.S. federal and state deferred tax liabilities—long term:
Total deferred tax liabilities	$ (1)	$ (16)
Components of Foreign Deferred Tax Assets and Liabilities [Abstract]
Total foreign deferred tax liabilities	(1)	(16)
U.S. Federal and State
U.S. federal and state deferred tax assets—long term:
Accrued payroll	376	525
Accrued expenses	21	0
Fixed assets	111	80
Intangibles	457	702
Research & development credit	1,464	1,257
Net operating loss	13,204	11,515
Stock compensation	539	772
New jobs credit	8	7
Total long-term assets	16,180	14,858
Total deferred tax assets	16,180	14,858
U.S. federal and state deferred tax liabilities—long term:
Fixed assets	0	0
Total deferred tax liabilities	0	0
Net deferred tax assets - long term	16,180	14,858
Less: Valuation allowance	(16,180)	(14,858)
Net deferred tax assets	0	0
Components of Foreign Deferred Tax Assets and Liabilities [Abstract]
Net operating loss	13,204	11,515
Total foreign deferred tax assets	16,180	14,858
Total foreign deferred tax liabilities	0	0
Foreign
U.S. federal and state deferred tax assets—long term:
Net operating loss	12	16
Total deferred tax assets	12	16
U.S. federal and state deferred tax liabilities—long term:
Total deferred tax liabilities	(13)	(32)
Components of Foreign Deferred Tax Assets and Liabilities [Abstract]
Net operating loss	12	16
Total foreign deferred tax assets	12	16
Intangibles	(13)	(32)
Total foreign deferred tax liabilities	(13)	(32)
Net foreign deferred tax liabilities	$ (1)	$ (16)

INCOME TAXES (Narrative) (Detai

INCOME TAXES (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Operating Loss Carryforwards [Line Items]
Provision for (benefit from) income taxes		$ 14,000	$ 22,000
State and Local Income Tax Expense (Benefit), Continuing Operations		1,000	1,000
Foreign income tax expense		(15,000)	(23,000)
Tax Cuts and Jobs Act of 2017, Change in tax rate, income tax expense (benefit)	$ 6,100,000
Increase of valuation allowance		1,300,000	6,200,000
Federal net operating loss carryforwards	47,000,000	47,000,000
State net operating loss carryforwards	46,900,000	46,900,000
Interest
Penalties		0	0
Significant uncertain tax positions	0	0	0
SWITZERLAND
Operating Loss Carryforwards [Line Items]
Net operating loss	$ 75,000	75,000
Engineering Design and Fabrication Advisory Services | Director
Operating Loss Carryforwards [Line Items]
Expenses from transaction with related party		$ 26,000	$ 42,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - Engineering Design and Fabrication Advisory Services - Director - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Aug. 31, 2016
Related Party Transactions
Due to related party, advisory services agreement		$ 16,000	$ 120,000
Expenses from transaction with related party	$ 26,000	$ 42,000

EMPLOYEE BENEFIT PLAN (Details)

EMPLOYEE BENEFIT PLAN (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
401(k) Savings Retirement Plan
Recorded plan matching contributions	$ 284	$ 204